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ABSTRACT 
 
Patients with type 1 diabetes complicated by end-stage renal disease (ESRD) have an 18 to 
30-fold higher standardized mortality-ratio compared to the general population. Comorbidities 
are more common and survival is worse among patients with diabetes on renal replacement 
therapy (RRT) compared to other RRT patients. Risks of ESRD and premature death among 
patients with type 1 diabetes have declined over the past decades. Yet, knowledge on factors 
affecting the improved prognosis and survival on RRT among patients with type 1 diabetes 
are limited. Our aim was to investigate whether survival of these patients has improved over 
time and how comorbidities, biochemical variables, and medication associate with mortality. 
 
Incident cohorts were studied here, including all patients with type 1 diabetes starting chronic 
RRT in Finland during the study periods. All data came from the Finnish Registry for Kidney 
Diseases, and information on medication was obtained from the FinDM diabetes database 
combining data from several Finnish registers including the Finnish Prescription Register. 
Patients were followed until death or end of follow-up. The main outcome measures were 
survival probability and relative risk of death according to observed factors. The survival of 
patients with type 1 diabetes on RRT changed between 1980 and 2005, and comorbidities 
(coronary artery disease, peripheral artery disease, heart failure, left ventricular hypertrophy, 
and cerebrovascular disease), biochemical variables (creatinine, albumin, urea, ionized 
calcium, phosphorus, hemoglobin, C-reactive protein, total cholesterol, high-density 
lipoprotein cholesterol, low-density lipoprotein cholesterol, trigycerides, and HbA1c), and use 
of medication (angiotensin-converting enzyme inhibitors, angiotensin reseptor blockers, 
calcium channel blockers, beta-blockers, statins, vitamin D, erythropoiesis-stimulating agents, 
and phosphate binders) associate with survival. Survival was assessed by Kaplan-Meier 
curves and relative risk of death by Cox proportional hazards regression. 
 
Median survival time of patients with type 1 diabetes on RRT increased continuously from 
3.60 years during 1980–1984 to more than 8 years in 2000–2005 and adjusted relative risk of 
death decreased 77% respectively. In unadjusted analyses, all monitored comorbidities at the 
start of RRT were significant predictors of mortality, and when analyzed in a multivariate 
model, peripheral artery disease (RR 1.9, 95% CI 1.3–2.8), left ventricular hypertrophy (RR 
1.7, 95% CI 1.2–2.4), and heart failure (RR 2.5, 95% CI 1.3–4.6) were all independent risk 
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factors of death. Analyses indicated that one third of deaths in the study population could be 
attributed to comorbidities. Lower serum creatinine and albumin, and elevated C-reactive 
protein, were predictors of mortality when measured before RRT start and adjusted for 
potential confounders. The use of medication was abundant and became more frequent when 
chronic kidney disease proceeded. Over two thirds of the patients used calcium channel 
blockers and beta-blockers before entering RRT. After adjustment for age and sex, lower 
relative risk of death was associated with utilization of calcium channel blockers (RR 0.71, 
95% CI 0.53–0.95) and vitamin D (RR 0.70, 95% CI 0.52–0.94) before RRT start. However, 
when adjusted further with comorbidities, BMI, and serum albumin, no significant association 
was evident with the use of any medication or mortality. 
   
In conclusion, the survival of patients with type 1 diabetes on RRT has improved over the 
past decades, and these patients have abundant comorbidity and medication. The results of 
this study indicate that it might be possible to improve survival further by prevention, early 
diagnosis, and treatment of comorbidities, treatment of malnutrition, proteinuria, 
hyperglycemia, chronic inflammation, and efficient RRT. Use of medication seems to keep 
survival of patients on an equal level to patients that don’t require the same medication. 
Randomized trials are needed in the future to confirm these findings.  
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ABSTRACT I FIISH 
 
Tyypin 1 diabetesta sairastavilla potilailla, joiden diabeettinen munuaistauti on edennyt 
uremian aktiivihoitoa (dialyysihoito tai munuaisensiirto) vaativaksi loppuvaiheen munuaisten 
vajaatoiminnaksi, on 18–30 -kertainen kuolemanriski muuhun väestöön verrattuna. Uremian 
aktiivihoidossa olevilla diabeetikoilla on enemmän muita sairauksia ja suurempi 
kuolemanriski kuin muilla uremian aktiivihoidossa olevilla potilailla. Viime vuosikymmeninä 
loppuvaiheen munuaisten vajaatoiminnan ja ennenaikaisen kuoleman riski on pienentynyt 
tyypin 1 diabeetikoilla. Kuolemanriskiin ja parantuneeseen ennusteeseen vaikuttavista 
tekijöistä uremian aktiivihoidossa olevilla tyypin 1 diabeetikoilla on kuitenkin vain vähän 
tutkimustietoa. Väitöskirjatutkimuksen tavoitteena oli selvittää, miten eloonjäämisennuste on 
muuttunut ja miten liitännäissairaudet, biokemialliset muuttujat ja lääkitys vaikuttavat siihen.   
 
Valitsimme tutkimukseen kaikki tutkimusaikana kroonisen uremian aktiivihoidon Suomessa 
aloittaneet potilaat, joiden munuaistaudin aiheuttajana oli tyypin 1 diabetes. Tiedot potilaista 
saimme Suomen munuaistautirekisteristä. Potilaiden käyttämä lääkitys selvitettiin FinDM-
tutkimuksen tietokannasta, jonka tiedot lääkityksen osalta tulevat Kansaneläkelaitoksen 
lääkekorvaustietokannasta. Potilaita seurattiin kuolemaan tai seuranta-ajan päättymiseen 
saakka. Tutkimme, kuinka näiden potilaiden eloonjäämisennuste on muuttunut vuosina 1980–
2005, miten liitännäissairaudet (sepelvaltimotauti, ahtauttava valtimonkovetustauti, sydämen 
vajaatoiminta, sydämen vasemman kammion hypertrofia ja aivoverenkiertohäiriö), 
biokemialliset muuttujat (kreatiniini, albumiini, urea, kalsium, fosfori, hemoglobiini, CRP, 
kokonaiskolesteroli, LDL-kolesteroli, HDL-kolesteroli, triglyseridit ja HbA1c) ja lääkitys 
(ACE-estäjät, angiotensiinireseptorin salpaajat, kalsiumkanavan salpaajat, beetasalpaajat, 
statiinit, D vitamiini, erytropoietiini johdoksineen ja fosfaatin sitojat) vaikuttavat 
eloonjäämisennusteeseen. Tilastollisessa analyysissä käytettiin Kaplan-Meier -käyriä 
eloonjäämisennusteen laskemiseen ja Coxin regressioanalyysia suhteellisen kuolemanriskin 
laskemiseen.  
 
Osoitimme, että verrattaessa vuosina 1980–1984 ja 2000–2005 uremian aktiivihoidon 
aloittaneita  tyypin 1 diabeetikoita, eloonjäämisennuste parani 3,6 vuodesta yli 8 vuoteen ja 
suhteellinen kuolemanriski aleni 77% myöhäisemmässä ryhmässä. Kaikki 
munuaiskorvaushoidon alkaessa raportoidut liitännäissairaudet lisäsivät kuolemanriskiä, ja 
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näistä monimuuttujamallissa analysoituna itsenäisiä kuolemanriskiä lisääviä tekijöitä olivat 
ahtauttava valtimonkovetustauti (suhteellinen riski 1,9, LV 1,3–2,8), sydämen vasemman 
kammion hypertrofia (suhteellinen riski 1,7, LV 1,2–2,4) ja sydämen vajaatoiminta 
(suhteellinen riski 2,5, LV 1,3–4,6). Kolmasosan kuolemista voidaan arvioida aiheutuneen 
raportoiduista liitännäissairauksista. Ennen uremian aktiivihoidon aloittamista mitattu 
matalampi seerumin kreatiniini ja albumiini sekä kohonnut CRP liittyivät lisääntyneeseen 
kuolemanriskiin myös sekoittavilla tekijöillä vakioinnin jälkeen. Lääkityksen käyttö oli 
yleistä näillä potilailla ja lisääntyi munuaistaudin edetessä. Yli kaksi kolmasosaa potilaista 
käytti kalsiumkanavan salpaajia ja beetasalpaajia ennen uremian aktiivihoidon aloitusta. 
Kalsiumkanavan salpaajien (suhteellinen riski 0,71, LV 0,53–0,95) ja D vitamiinin 
(suhteellinen riski 0,70, LV 0,52–0,94) käyttöön liittyi pienempi kuolemanriski ikä- ja 
sukupuolivakioinnin jälkeen, mutta vakiointi muilla sekoittavilla tekijöillä hävitti tämän 
yhteyden.  
  
Uremian aktiivihoidossa olevien tyypin 1 diabeetikoiden eloonjäämisennuste on parantunut 
viime vuosikymmeninä, vaikka heillä on paljon liitännäissairauksia ja lääkityksiä. 
Tutkimuksemme tulokset viittaavat siihen, että eloonjäämisennusteen parantaminen edelleen 
saattaa olla mahdollista ehkäisemällä, ajoissa toteamalla ja tehokkaasti hoitamalla näiden 
potilaiden liitännäissairauksia. Myös aliravitsemuksen, proteinurian, hyperglykemian ja 
kroonisten tulehdusten hoito sekä tehokas dialyysihoito vaikuttavat tärkeiltä. Lääkityksellä 
saadaan lääkitystä tarvitsevien potilaiden eloonjäämisennuste samalle tasolle kuin niiden, 
jotka eivät lääkitystä tarvitse. Satunnaistettuja tutkimuksia tarvitaan löydöstemme 
varmistamiseksi.  
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ITRODUCTIO 
 
Diabetic nephropathy is one of the most serious complications of type 1 diabetes, especially 
when progressed to end-stage renal disease (ESRD). When comparing to the general 
population, patients with type 1 diabetes complicated by ESRD have a standardized mortality 
ratio of 18 to 30 (Groop, et al., 2009; Orchard, et al., 2010). Especially in Finland where the 
incidence of type 1 diabetes is the highest in the world (Harjutsalo, et al., 2008), type 1 
diabetes is a major cause of ESRD accounting for 16% of all patients on renal replacement 
therapy (RRT) (dialysis and kidney transplantation) (Finnish Registry for Kidney Diseases, 
2012). 
The risk of ESRD has decreased among patients with type 1 diabetes during the past decades 
(Finne, et al., 2005). However, regardless of continuous development of dialysis treatment 
and diabetes management, and decreased mortality among other RRT patients (USRDS 
annual data report, 2013), there is a scarcity of and conflicting data on possible improvements 
in survival of patients with type 1 diabetes on RRT (Van Dijk, et al., 2005; Villar, et al., 2007). 
The knowledge of factors that might have an effect on survival among patients with type 1 
diabetes on RRT is also limited. Comorbidities have been shown to increase mortality among 
ESRD patients (van Manen, et al., 2007), and ESRD patients with diabetes (type 1 and type 2 
combined) have more comorbidities and worse survival compared to other ESRD patients 
(Foley, et al., 1997; Lok, et al., 2004). High glycosylated hemoglobin (HbA1c) and 
cholesterol predict worse survival among patients with type 1 diabetes without ESRD 
(Rossing, et al., 1996; Shankar, et al., 2007; Soedamah-Muthu, et al., 2008); but when 
diabetes (type 1 and type 2) is complicated with ESRD the evidence is contradictory (Morioka, 
et al., 2001; Racki, et al., 2007; Smavatkul, et al., 2007; Williams, et al., 2006; Williams, et al., 
2010). Results on the usefulness of hemoglobin, creatinine, and glomerular filtration rate as 
predictors of mortality among these patients have been conflicting (Conway, et al., 2008; 
Coronel, et al., 2009; Foley, et al., 1997; Morioka, et al., 2001). 
In patients with type 1 diabetes, medication is one of the most important means to improve 
prognosis and to slow down the progression of renal insufficiency during the predialysis 
phase. Angiotensin-converting enzyme inhibitors and statins seem beneficial in patients with 
diabetes in attempt to prevent nephropathy, progression of nephropathy, and premature death 
(Adult treatment panel III, 2002; Heart Outcomes Prevention Evaluation Study Investigators, 
2000; Heart protection Study Collaborative Group, 2002; Lewis, et al., 1993). However, the 
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results of the association of drug utilization and survival in ESRD patients are contradictory 
(Foley, et al., 2002; Ishani, et al., 2004; Kestenbaum, et al., 2002) and non-existing among 
patients with type 1 diabetes and ESRD. 
In conclusion, patients with type 1 diabetes on RRT have high risk of premature death, and 
previous results have shown that factors predicting survival among RRT patients with and 
without diabetes (type 1 and type 2) are not the same. The knowledge on possible 
improvement of survival and factors affecting it among patients with type 1 diabetes on RRT 
is scarce. This knowledge would be essential in attempt to improve survival of these patients. 
Therefore changes in survival over the last decades were reviewed, along with which factors 
associate with survival for patients with type 1 diabetes on RRT. 
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REVIEW OF THE LITERATURE 
 
1. Type 1 diabetes 
1.1 Classification 
 
Diabetes mellitus is classified as a group of metabolic disorders where blood glucose 
concentration is elevated to a level that causes symptoms and possibly organ damage. 
Elevation of blood glucose is caused by inadequate insulin secretion, decreased insulin action, 
or both. Symptoms of hyperglycemia include fatigue, polydipsia, polyuria, weight loss, and 
blurred vision. Life-threatening, acute consequences of hyperglycemia are ketoacidosis and 
hyperosmolar hyperglycemic nonketotic syndrome. Long-term complications of diabetes are 
caused by micro- and macrovascular diseases manifestating especially in kidneys, eyes, 
extremities, peripheral and autonomic nerves, and the cardiovascular system.   
The definition of diabetes is based on plasma glucose measurements. Diabetes is diagnosed if 
fasting plasma glucose is ≥7.0 mmol/l or plasma glucose is ≥11.1 mmol/l two hours after 75 g 
oral glucose intake or HbA1c is ≥6.5% (48 mmol/mol). If one plasma glucose measurement is 
over 11.1 mmol/l combined with symptoms implying diabetes (thirst, polyuria, weight loss), a 
diabetes diagnosis is warranted (American Diabetes Association, 2013; World Health 
Organzation, 2006). These limits are set to the level above which premature mortality, 
microvascular, and cardiovascular complications resulting from hyperglycemia are increased. 
According to World Health Organization guidelines (2006), intermediate hyperglycemia is 
diagnosed if fasting plasma glucose is 6.1–6.9 mmol/l (impaired fasting glucose) or plasma 
glucose is 7.8–11.0 mmol/l two hours after oral ingestion of 75 g glucose load (impaired 
glucose tolerance). An oral glucose test should be performed, if fasting glucose concentration 
is 6.1–6.9 mmol/l. Otherwise, 30% of the patients with inadequate insulin response to glucose 
intake will not be diagnosed as having diabetes. The American Diabetes Association (2013) 
has set lower limits to detect people with increased risk for diabetes. According to these 
guidelines, intermediate hyperglycemia is diagnosed when fasting plasma glucose 
concentration is 5.6–6.9 mmol/l or HbA1c 5.7–6.4%.  
Diabetes has traditionally been divided into two groups.  In type 1 diabetes, lack of insulin 
secretion is caused by immune-mediated destruction of pancreatic insulin-secreting islet beta-
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cells. Type 2 diabetes is caused by deficient insulin action, when response to insulin in target 
tissues is diminished (insulin resistance) and insulin secretion is inadequate to compensate 
this (National Diabetes Data Group, 1979). However, there is a wide overlap between these 
two groups as a metabolic syndrome with insulin resistance can be found in over one-third of 
the patients with type 1 diabetes. Among patients with type 1 diabetes and end-stage renal 
disease, metabolic syndrome is even more common (Thorn, et al., 2005). A few decades ago, 
all children with diabetes were diagnosed as having type 1 diabetes, but differentiation of 
diabetes diagnosis by age is misleading. Obesity among children is increasing (Li, et al., 
2008), and hence a notable proportion of children with diabetes have type 2 diabetes, 
especially in populations with a low incidence of type 1 diabetes (CDC, 2011; Dabelea, et al., 
2007). Diagnostic problems also occur in young patients with diabetes who have pancreatic 
autoantibodies but otherwise phenotype of type 2 diabetes (Klingensmith, et al., 2010; 
Reinehr, et al. 2006). In addition to type 1 and type 2 diabetes, there are other forms of 
diabetes. Latent autoimmune diabetes in adults (LADA) is pathophysiologically similar to 
type 1 diabetes, but disease progress is slower and it is diagnosed usually in adulthood. 
Clinical outcome of the disease is similar to type 2 diabetes, and insulin therapy is not 
required at the time of diagnosis, but insulin dependency usually develops over time (Pozzilli, 
et al., 2001). Maturity-onset diabetes of the young (MODY) is heterogenous group of 
inheritant disorders causing nonketotic diabetes. MODY develops usually before 25 years of 
age, and is typically caused by pancreatic beta-cell dysfunction. The disease can result from 
mutation in one of at least six genes expressing in beta-cells (Fajans, et al., 2001). Other 
forms of diabetes include gestational diabetes and diabetes caused by loss of pancreatic tissue 
because of inflammation, trauma, or surgery. Consequently, diagnosis of type 1 diabetes is 
not always clear and development of genetic and molecular characterisation of diabetes may 
lead to more defined subgroups and treatment strategies (Tuomi, et al., 2013). 
 
1.2 Pathogenesis 
 
Type 1 diabetes is an autoimmune disease, where autoreactive T-cells and autoantibodies 
cause cellular-mediated destruction of the islet beta-cells of the pancreas (Bluestone, et al., 
2010). Autoantibodies to islet cells, insulin, glutamic acid decarboxylase, and tyrosine 
phosphatases IA-2 and IA-2 beta are present in 85–90% of patients when the disease is 
diagnosed (American Diabetes Association, 2013; Expert Committee on the Diagnosis and 
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Classification of Diabetes Mellitus, 1997). There is also strong association to some HLA 
alleles (Huang, et al., 1996), and patients are prone to other autoimmune diseases (Larizza, et 
al., 2012).  
The rate of beta-cell destruction determines the time of the onset of the disease. When 
destruction is fast, dependece on insulin therapy appears rapidly, and patients are at risk of 
severe hyperglycemia and ketoacidosis. When the disease progresses slowly, residual insulin 
secretion can prevent ketoacidosis for many years. The incidence of type 1 diabetes has 
increased rapidly during the last decades (Green, et al., 2001). Because of improved survival, 
nowadays only few patients with type 1 diabetes die before reaching the age of fertility. This 
enables the possibility to transfer the genetic risk of type 1 diabetes to offspring. The risk of 
type 1 diabetes is increased in the offspring of patients with type 1 diabetes of Caucasoid 
origin, and is 2–4% if the mother is affected, and 5–8% if the father is affected compared to 
0.4% with no family history (Groop, et al., 2014). Nevertheless, genetic factors cannot alone 
explain this increase, and environmental factors seem to play an important role at onset 
(Hermann, et al., 2003). A study from Finland showed that the prevalence of type 1 diabetes 
among Somalian children born in Finland was similar to the background population, although 
the prevalence of type 1 diabetes in Somalia is markedly lower than in Finland. This 
highlights the importance of exogenous factors in the development of type 1 diabetes (Oilinki, 
et al., 2011). However, knowledge remains scarce regarding the environmental factors that are 
sensitizing to the onset of type 1 diabetes. Enterovirus infection and dietary antigens (e.g. 
bovine insulin) are the strongest candidates for the factors that might trigger the process 
leading to type 1 diabetes (Coppieters, et al., 2011; Knip, et al., 2011). Gut microbiota may 
expose the immune system to these triggering factors (Vaarala, 2012). Another explanation 
for the growing incidence in children is lack of environmental factors that were previously 
present, which would cause the underused immune system to attack its own cells (Gale, 2005).    
 
1.3 Epidemiology 
 
The incidence of type 1 diabetes varies widely in the world as was shown in a large 
multinational study (The Diamond Project Group, 2006). In this study, the age-adjusted 
incidence was the lowest in China and Venezuela (0.1 per 100 000 per year) and the highest 
in Finland (40.9 per 100 000 per year) (Figure 1).  
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Figure 1. Incidence of type 1 diabetes worldwide 1990-1999 
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Figure modified from The Diamond Project Group, 2006 
 
The incidence of type 1 diabetes in Finnish children has increased from 31.4 per 100 000 per 
year in 1980 to 64.2 per 100 000 per year in 2005 (Harjutsalo, et al., 2008). The increase has 
been most remarkable in children aged 0–4 years. However, this increase has been followed 
by a plateau since 2005 (Harjutsalo, et al. 2013), which is in line with the results from Sweden 
(Berhan, et al., 2011). Similar results of increasing incidence are reported from other 
European countries with 3.2% annual increase in incidence (Green, et al., 2001). Seasonal 
alteration in incidence was also shown; onset of the disease was less common during the 
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summer months. This implies to a role for environmental factors in the onset of type 1 
diabetes. Although the incidence in children has increased, the overall incidence has not 
increased in Belgium and Sweden, because the incidence among adults has decreased 
(Pundziute-Lyckå, et al., 2002; Weets, et al., 2002). This could mean that type 1 diabetes 
manifests earlier in age than previously. However, a recent study in Finland reported that the 
incidence among young adults (15–39 years old) increased annually by 3.9% during the 
follow-up in 1992–2001. The increase in incidence was similar to that in children (4.2%) 
(Lammi, et al., 2008). Boy-to-girl ratio in type 1 diabetes incidence is 0.9–1.0 in children, but 
male excess is noted for adult-onset disease by ratio 1.6 (Harjutsalo, et al., 2008, Weets, et al., 
2002). The onset of type 1 diabetes has shifted to earlier age, and the overall incidence has 
increased at least in Finland. However, the reason for this change remains unclear.   
 
1.4 Treatment 
 
Diabetes was recognized as a clinical entity in 1812, and there was no effective treatment 
until the discovery of insulin in 1923. Insulin deficiency led to patient death within weeks to 
months after diagnosis without treatment (Polonsky, 2012). The treatment of type 1 diabetes 
is based on insulin therapy. Disposable insulin syringes reached wider use in the 1970s, and 
home glucose monitoring and semisynthetic and synthetic human insulin become available in 
the 1980s. The emergence of rapid-acting insulin regimens in the 1980s led to the 
development of a multiple insulin injection treatment, where long-acting insulin is injected 
subcutaneously 1–2 times per day and rapid-acting insulin administered before a meal, which 
enables more stable blood glucose control (Figure 2). Another option is insulin-pump therapy, 
which provides continuous subcutaneous insulin infusion and a possibility to achieve better 
glycemic control (Pickup, et al., 2012). Regular glucose self-monitoring several times a day is 
required to adjust doses of insulin therapy. Development of continuous glucose monitoring 
combined with insulin-pump therapy will probably make blood glucose control better 
controllable in the future (Siegmund, et al., 2013). 
Normoglycemia without the fear of hypoglycemia can be obtained by pancreas transplantation 
(Fioretto, et al., 1993). However, surgical complications and immunosuppressive treatment 
are the main problems of this treatment (Gruessner, et al., 2011). Transplantation of human 
pancreatic islet cells can also provide an option to treat type 1 diabetes (Robertson, 2010; 
Vaithilingam, et al., 2011). The first results from pancreatic islet transplantations were 
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promising (Shapiro, et al., 2000), but a five-year follow-up study after islet transplantation 
showed that only ~10% maintained insulin independence (Ryan, et al., 2005). In the future, 
newly diagnosed type 1 diabetes could be treated with antigen-specific treatments. These 
immune therapies (vaccination, and immunosupressive and immunomodulative agents) act by 
modulating T-cell action in attempt to stop the autoimmune destruction of pancreatic beta-
cells (Bluestone, et al., 2010; Michels, et al., 2011; Peakman, 2012).  
 
Figure 2. Multiple insulin injection treatment of type 1 diabetes 
 
 
1.5 Diabetic nephropathy 
 
Years of hyperglycemia can cause micro- and macrovascular complicatons. Macrovascular 
complications may affect heart, brain, and peripheral blood vessels, and microvascular 
complications are manifested primarily in eyes, peripheral and autonomic nerves, and kidneys. 
Early diagnosis and effective treatment of diabetic nephropathy is essential, because it 
increases mortality significantly (Groop, et al., 2009; Orchard, et al., 2010).  
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1.5.1 Classification 
 
Proteinuria and progression from hyperfiltration to gradual decrease of glomerular filtration 
rate are the signs of nephropathy in type 1 diabetes. Diabetic nephropathy, especially when 
proceeded to clinical albuminuria, increases the risk of cardiovascular diseases (Tuomilehto, 
et al., 1998) and decreases survival significantly (Borch-Johnsen, et al., 1985, Groop, et al., 
2009, Rossing, et al., 1996). 
Microalbuminuria as the sign of diabetic nephropathy is diagnosed when the urinary albumin 
excretion rate is repeatedly 20–200 µg/min. Macroalbuminuria means albumin excretion rate 
≥ 200 µg/min. An alternative way to examine urinary albumin excretion is the measurement 
of albumin and creatinine from a urine sample. Albumin/creatinine values 2.5–25 mg/mmol in 
men and 3.5–35 mg/mmol in women are considered to be microalbuminuria and values above 
those macroalbuminuria. Kidney function is normally assessed by glomerular filtration rate 
(GFR). When kidney function deteriorates and GFR decreases to lower than 15 ml/min, a 
patient is classified as having end-stage renal disease (ESRD) and requires renal replacement 
therapy (RRT). New classification of chronic kidney disease (CKD) divides it into stages 1 to 
5, and stage 5 CKD equals the term ESRD used in this text. 
Measurement of inulin clearance is the gold standard for the determination of GFR (Smith, 
1951), but not suitable for screening. Serum creatinine is commonly used to evaluate kidney 
function and calculate GFR. The formulas proposed by Cockcroft and Gault (Cockcroft, et al., 
1976), Modification of Diet in Renal Disease (MDRD) (Levey, et al., 1999), and the chronic 
kidney disease epidemiology collaboration (CKD-EPI) equation (Levey, et al., 2009) are the 
most commonly used to estimate GFR. MDRD is suitable for GFR estimation in advanced 
CKD, and the CKD-EPI equation performs better at higher GFRs (Earley, et al., 2012). 
Because these formulas cannot eliminate all other factors than creatinine filtration affecting 
serum creatinine concentration, other serum markers for renal function have been studied. 
Serum cystatin C appears to be better than creatinine to estimate GFR (Kyhse-Andersen, et al., 
1994; Simonsen, et al., 1985). Higher costs of cystatin C and estabilished clinical practise in 
creatinine use have, however, prevented widespread use of cystatin C. 
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1.5.2 Epidemiology 
 
Table 1 shows reported cumulative incidence rates of nephropathy (persistent proteinuria) in 
patients with type 1 diabetes.  
 
Table 1. Incidence of nephropathy among patients with type 1 diabetes 
Study, year Country Year of 
type 1 
diabetes 
diagnosis 
Number 
of 
patients 
Follow-up  Incidence of 
diabetic 
nephropathy 
Comments 
Andersen, et 
al., 1983 
Denmark Before 
1953 
1303 40 years 45% A male 
preponderance 
Kofoed-
Enevoldsen, 
et al,. 1987 
Denmark 1933–
1972 
2890 At least 
11 years 
20% Incidence peak 
after 15–17 years 
from diabetes 
diagnosis 
Bojestig, et 
al., 1994 
Sweden 1961–
1980 
213 20 years 10% Decline in 
incidence from 
28% to 6% during 
study period 
Rossing, et 
al., 1995 
Denmark 1965–
1979 
356 15 years 16–20% No decline in 
incidence 
Hovind, et 
al., 2003 
Denmark 1965–
1984 
600 20 years 14–31% Significant 
decline in 
incidence during 
study period 
Nephropathy was diagnosed if at least two urine samples contained albumin ≥300 mg/24 h or ≥300 
mg/liter. 
 
An older study reported 45% cumulative incidence of nephropathy after 40 years from the 
diagnosis of type 1 diabetes (Andersen, et al., 1983). The incidence of nephropathy decreased 
30% from patients with type 1 diabetes diagnosed in the 1930s to patients diagnosed in the 
1950s (Kofoed-Enevoldsen, et al., 1987). A Swedish study showed 20-year cumulative 
incidence decreasing from 28% in patients diagnosed with type 1 diabetes in 1961–1965 to 
5.8% in patients diagnosed in 1971–1975 (Bojestig, et al., 1994), and Hovind, et al. (2003) 
reported similar results: The 20-year incidence of type 1 diabetic nephropathy decreased from 
31% to 14% when the patients with type 1 diabetes diagnosed in 1965–1969 were compared 
to the patients diagnosed in 1979–1984. However, a Danish study of patients with type 1 
diabetes diagnosed in 1965–1979 could not find any decline in the incidence of diabetic 
nephropathy (Rossing, et al., 1995). The reason for these conflicting results is unknown. 
Some of the patients with nephropathy develop end-stage renal disease. Finne et al (2005) 
reported that the cumulative incidence of end-stage renal disease among patients with type 1 
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diabetes has declined, and is 2.2% at 20 years and 7.8% at 30 years after diabetes diagnosis. 
The peak of the incidence of diabetic nephropathy is seen after 15–17 years of diabetes 
duration (Andersen, et al., 1983; Kofoed-Enevoldsen, et al., 1987).  
 
1.5.3 Development 
 
Nephropathy in type 1 diabetes usually develops slowly as shown in Table 2.  
 
Table 2. Development of nephropathy in type 1 diabetes 
Stage Time from 
diagnosis of 
diabetes 
Glomerular 
filtration rate 
Albumin 
excretion 
Blood pressure 
Acute renal 
hypertrophy/ 
hyperfunction 
Present at 
diagnosis, 
reversible 
Increased by 20–
50% 
Normal or 
increased but 
reversible 
Normal 
Normoalbuminuria 0–5 years Increased by 20–
50% 
Normal Normal 
Microalbuminuria 6–15 yearsa Normal–
supranormal, 
declining  
Increase ≈ 20% / 
yearb 
Incipient increase 
≈ 3 mmHg/yearb  
Overt diabetic 
nephropathy 
15–25 yearsa Decline ≈ 10 
ml/min/yearb 
Progressive 
clinical 
proteinuriab 
High blood 
pressure, increase 
by ≈ 5 mmHg 
/yearb  
End-stage renal 
disease 
≥ 25 yearsa < 10 ml/min Often some 
decline due to 
nephron closure 
Highb 
aIn patients who develop diabetic nephropathy  
bWithout treatment 
Table modified from Mogensen, 1999 
 
Microalbuminuria is typically the first sign of nephropathy (Mogensen, 1987). Pathological 
changes in kidneys start from increased glomerular size and increased basement membrane 
thickness, and develop gradually to mesangial expansion and advanced glomerulopathy. A 
typical finding in kidney biopsy is nodular glomerulosclerosis, but diffuse glomerulosclerosis 
is also possible (Østerby, 1996). Progressive proteinuria is of glomerular origin and is 
followed by decrease in glomerular filtration rate. Hyperglycemia and hypertension are the 
main factors in the development of nephropathy, but genetic factors play an important role 
(Mogensen, 1999; Parving, 1998). Microalbuminuria and macroalbuminuria can be reversible 
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with intensive treatment of hyperglycemia and hypertension (The diabetes control and 
complications trial research group, 1993; Lewis, et al., 1993 and 2001). 
 
1.5.4 Risk factors 
 
Microalbuminuria is a risk factor for progression of diabetic nephropathy and risk of death 
increases with severity of renal disease (Groop, et al., 2009; Viberti, et al., 1982; Yokoyama, 
et al., 2011). Only some microalbuminuria patients develop macroalbuminuria or ESRD 
(Forsblom, et al., 1992). However, already borderline microalbuminuria 14–21 µg/min is 
associated with significantly increased risk of renal disease progression and cardiovascular 
death (Rachmani, et al., 2000) 
Hyperglycemia is a major factor in the development of diabetic nephropathy (Alaveras, et al., 
1997, Waden, et al., 2009). The risk of microalbuniuria increases rapidly when HbA1c is over 
8.1% (Krolewski, et al., 1995), and the incidence of diabetic nephropathy decreases and the 
risk of declined GFR is significantly lower with intensive treatment of hyperglycemia (The 
diabetes control and complications trial research group, 1993; The DCCT/EDIC Research 
Group, 2011). 
Hypertension is essentially associated with diabetic nephropathy. Blood pressure increases 
during the progression of renal disease, but hypertension is also a risk factor of nephropathy 
(Mogensen, 1999; Rossing, et al., 1993) and antihypertensive treatment reduces progression 
of diabetic nephropathy (Casas, et al., 2005). Guidelines recommend angiotensin-converting-
enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) when treating 
hypertension in patients with diabetic nephropathy. A randomized trial showed that ACEI use 
reduces the progression of nephropathy in patients with type 1 diabetes (Lewis, et al., 1993), 
and two randomized studies reported on the beneficial effect of ARBs on nephropathy among 
patients with type 2 diabetes (Brenner, et al., 2001; Lewis, et al., 2001). However, a meta-
analysis could not show an additional renoprotective effect of ACEIs or ARBs beyond 
lowering blood pressure in diabetic patients (Casas, et al., 2005). Although dietary sodium 
intake restriction is recommended for treatment of hypertension, type 1 diabetic patients with 
the lowest sodium intake seem to have higher risk of ESRD and mortality (Thomas, et.al, 
2011). 
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Mannose-binding lectin and high-sensivity C-reactive protein as the markers of low-grade 
inflammation has been shown to associate with increased risk of progression of diabetic 
nephropathy (Hansen, et al., 2010).  
Dyslipidemia has been shown to associate with microproteinuria and declined GFR in type 1 
diabetes patients (Demirel, et al., 2013; Bulum, et al., 2013), and these results suggest that 
dyslipidemia may play a role in the pathogenesis of diabetic nephropathy. Also metabolic 
sydrome and physical inactivity increases the risk for diabetic nephropathy (Thorn, et al., 
2009; Wadén, et al., 2008). 
Cigarette smoking increases the incidence and the risk of progression of diabetic nephropathy. 
Albuminuria can also improve if smoking is ceased (Chase, et al., 1991; Christiansen, 1978; 
Sawicki, et al., 1994).  
Genetic susceptibilty also plays a role in the development of diabetic nephropathy, and the 
strongest associations with diabetic nephropathy have been shown at the FRMD3 and CARS 
genomic loci (Pezzolesi, et al., 2009). Puberty and sex hormones may have an influence on 
development and progression of diabetic nephropathy, because there is markedly higher risk 
of ESRD due to diabetic nephropathy among male compared to female patients, especially 
when diabetes is diagnosed after puberty (Möllsten, et al., 2010).   
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Table 3. Risk factors of development and progression of nephropathy in patients with type 1 
diabetes 
Study, year Country Patients Number 
of 
patients 
Prognostic factor  Results 
Krolewski, et 
al., 1995 
United 
States 
IDDM 1613 HbA1c Risk of microalbuminuria 
increases rapidly when 
HbA1c is over 10.1% 
Waden, et al., 
2009 
Finland Type 1 diabetes 2102 HbA1c HbA1c is independently 
associated with progression 
of diabetic nephropathy 
The 
DCCT/EDIC 
Research 
Group, 2011 
United 
States 
Type 1 diabetes 1441 Hyperglycemia The risk of an impaired 
GFR was lower among 
persons treated with 
intensive diabetes therapy 
Rossing, et 
al., 1993 
Denmark IDDM and 
proteinuria 
41 Diastolic blood 
pressure 
Diastolic blood pressure is 
correlated with decline in 
glomerular filtration rate 
Viberti, et al., 
1982 
NA IDDM 87 Microalbuminuria Microalbuminuria predicts 
progression of diabetic 
nephropathy 
Bulum, et al., 
2013 
Croatia Type 1 diabetes 313 Dyslipidemia Dyslipidemia is associated 
with an impaired GFR 
Thorn, et al., 
2009 
Finland Type 1 diabetes 3783 Metabolic 
syndrome 
Metabolic sydrome is a risk 
factor for progression of 
diabetic nephropathy 
Chase, et al., 
1991 
United 
States 
IDDM 359 Cigarette smoking Smoking is associated with 
development and 
progression of nephropathy 
Hansen, et al., 
2010 
Finland Type 1 diabetes 1564 Inflammation Low-grade inflammation 
associates with progression 
of diabetic nephropathy 
Pezzolesi, et 
al., 2009 
United 
States 
Type 1 diabetes 1705 Genes FRMD3 and CARS 
genomic loci are associated 
with susceptibillity to 
diabetic nephropathy 
Möllsten, et 
al., 2010 
Sweden Type 1 diabetes 11 681 Gender and age at 
diabetes diagnosis 
The risk of ESRD due to 
diabetic nephropathy is the 
highest among male 
diagnosed at age 20–34 
years 
IDDM; Insulin dependent diabetes mellitus, NA; Not available 
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2. End-stage renal disease 
2.1 Ethiology and epidemiology 
 
In end-stage renal disease (ESRD) the kidneys are unable to maintain low levels of urea, 
normal hematocrit, sodium and potassium, and water and acid-base balance. Therefore renal 
replacement therapy (RRT) is needed (Mitch, 2012). Loss of renal function without RRT 
would cause life-threatening hyperkalemia, acidosis, uremia, and/or fluid retention. Even on 
RRT, patients with ESRD manifest several clinical problems: e.g. equilibrium of calcium and 
phosphorus leading to calcification of vessels and soft tissues, and renal osteodystrophy, 
hypertension, anemia, and changes in blood coagulation.  
The incidence of ESRD varies widely globally and is usually assessed by the incidence of 
RRT patients. However, ESRD patients’ inclusion criteria to RRT varies between countries. 
According to the ERA-EDTA registry (Annual report 2011), the annual incidence of RRT in 
Europe varies from 85 new patients per million population in Finland to 203 per million in 
Greece. In Mexico, the annual incidence is 527 new patients per million population and in 
Bangladesh only 32 patients per million population (USRDS annual data report: 2013 Atlas of 
CKD and ERSD). The difference in the incidence is partly explained by the available funding, 
especially in developing countries. However, an increased number of patients with diabetes 
and ESRD explain the high incidence rates in some countries. For example, in Mexico, 
diabetes is the cause of end stage renal disease in almost 60% of the patients starting RRT. 
Type 1 and type 2 diabetes are the most important causes to start RRT in Finland (Figure 3). 
In most of the countries, type 2 diabetes is a far more common cause of ESRD than type 1 
diabetes, but in the countries with a high incidence of type 1 diabetes like Finland, Sweden, 
Denmark, and the United Kingdom, type 1 diabetes is the cause of ESRD in 40% of the 
diabetes-caused ESRD cases. In Finland, the incidence of RRT caused by type 2 diabetes 
increased remarkably in the 1990s, but has been stable since 2000 as well as the incidence of 
new RRT patients with glomerulonephritis, polycystic kidney disease, and nephrosclerosis. 
The incidence of ESRD caused by type 1 diabetes has decreased slightly after the year 2000, 
and the incidence of ESRD caused by amyloidosis and pyelonephritis has decreased 
drastically (Figure 1).  
Approximately two-thirds of the ESRD patients are men, and the median age is around 60–70 
years at the start of RRT. Kastarinen et al (2010) reported that obesity, hypertension, diabetes, 
and male gender are independent risk factors for ESRD. The incidence of RRT has been 
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rather stable during the last decade. However, the prevalence of RRT has increased at the 
same time due to improved survival. The prevalence of RRT in Finland is 805 patients per 
million population, and varies elsewhere from 159 RRT patients per million population in the 
Philippines to 2309 per million population in Japan (Finnish Registry for Kidney Diseases, 
Report, 2012; USRDS annual data report: 2013 Atlas of CKD and ERSD).  
 
Figure 3. Incidence of RRT according to ethiology 
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Finnish Registry for Kidney Diseases, Report, 2012 
 
2.2 Treatment 
2.2.1 Hemodialysis and peritoneal dialysis 
 
Hemodialysis is the most common treatment modality at the initiation of RRT. It has been 
used in chronic kidney disease since the 1960s. Infections are common complications with 
hemodialysis catheters and therefore arteriovenous fistula or graft is a more preferable 
vascular access in chronic hemodialysis (Bagdasarian, et al., 2012). Diabetes, age, and 
peripheral artery disease may provide problems in arteriovenous fistula patency (Smith, et al., 
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2012). Hemodialysis three times per week at hospital is the most common protocol, but daily 
dialysis at home provides more flexibility for the patient. 
Peritoneal dialysis allows more independence than hemodialysis, costs are significantly lower, 
and survival rates are comparable to hemodialysis (Fenton, et al., 1997; Mehrotra, et al., 2011; 
Rodriquez, et al., 2011; Sinnakirouchenan, et al., 2011). Peritoneal dialysis can be a beneficial 
choice for younger patients without diabetes during the first years on RRT, but older patients 
with diabetes seem to benefit from hemodialysis, and hemodialysis has a survival advantage 
after longer duration of RRT (Collins, et al., 1999; Heaf, et al., 2002; McDonald, et al., 2009; 
Vonesh, et al., 2006). Infection is the most common problem in peritoneal dialysis and may 
prevent the use of it. Increased peritoneal permiability, loss of ultrafiltration, and peritoneal 
fibrosis, processes accelerated in diabetes, can also lead to technique failure (Locatelli, et al., 
2004).  
 
Figure 4. Prevalence of RRT at end of year in Finland according to type of treatment  
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Finnish Registry for Kidney Diseases, Report, 2012 
 
In Finland in 2012, 7% of the RRT patients used peritoneal dialysis, 33% hemodialysis, and 
almost 60% had a functioning kidney transplant (Figure 4) (Finnish Registry for Kidney 
Diseases, Report 2012). Among patients with type 1 diabetes as the cause of ESRD, the 
corresponding figures were 10% in peritoneal dialysis, 23% in hemodialysis, and 67% with 
kidney transplant. In 2011, peritoneal dialysis was used in 19% of dialysis patients in Finland, 
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which is equal to other nordic countries. However, peritoneal dialysis was a much less 
common dialysis modality for example in the United States (7%) and Japan (3%), and far 
more common in Hong Kong (74%) and Mexico (49%) (USRDS annual data report, 2013).  
 
2.2.2 Kidney transplantation 
 
Successful kidney transplantation offers the best quality of life for ESRD patients (Jofré, et al., 
1998). Survival in patients treated with kidney transplantation is better than with hemodialysis 
or peritoneal dialysis (USRDS annual data report, 2013; ERA-EDTA annual report, 2011). 
However, patient groups of transplant recipients and non-recipients are not comparable and 
this causes a bias, which is almost impossible to control by statistical adjustments. 
Unfortunately the number of patients on a kidney transplantation waiting list far exceeds the 
number of donors. The annual number of transplantations in Finland has remained about the 
same for 20 years and the prevalence of RRT patients has increased, which has led to 
increased waiting time on dialysis before first kidney transplantation (Figure 5).  
 
Figure 5. Time elapsed before first kidney transplantation after start of RRT (Finnish 
Registry for Kidney Diseases 1965–2008) 
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Type 1 diabetes is the most common cause of kidney transplantation in Finland, but when 
related to patient-years in dialysis, patients with polycystic kidney disease receive kidney 
transplant most often. Overall, the number of kidney transplantations related to patient-years 
in dialysis has decreased markedly (Figure 6). Almost all kidney transplants (98%) come from 
deceased donors in Finland, but for example in the United Kingdom, Norway, Sweden, and 
Denmark, more than one-third of kidney transplant recipients receive an organ from a living 
donor. This reflects the lower transplantation rates in Finland in 2010 (33 per million 
population) compared to the prementioned countries (41–61 per million population) (ERA-
EDTA annual report, 2011). However, the prevalent rate of functioning grafts in Finland 2011 
(474 per million population) was comparatively good on an internatonal level (USRDS annual 
data report, 2013).  
 
Figure 6. Kidney transplantations related to patient-years in dialysis according to diagnosis 
(Finnish Registry for Kidney Diseases 1985–2008) 
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Patients with type 1 diabetes and ESRD can also be treated by simultaneous kidney-pancreas 
transplantation, which enables discontinuity or reduction of insulin treatment and achievement 
of better glucose balance.  
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However, transplantation has risks associated with surgical procedures, and 
immunosuppressive therapy after transplantation can cause side effects, predispose to 
infections, and have interactions with other medication. Before the millenium shift, the 
combination of cyclosporin, azathioprine, and steroids was the most common 
immunosuppressive medication at the end of the year that kidney transplantation was 
performed. Thereafter, the most common combination has been cyclosporin and 
mycophenolate in various combinations. Tacrolimus is used as an alternative to cyclosporin in 
a quarter of the transplant recipients. The use of steroids has diminished considerably during 
the past decade (Finnish Registry for Kidney Diseases, Report 2008).  
 
2.3 Survival 
2.3.1 Survival and causes of death 
 
Mortality among patients on RRT is high, and five-year survival is 47%. Due to better 
survival of patients with kidney transplantation, patients on dialysis have even worse survival; 
only 36–39% of them are alive after five years on dialysis, and adjusted mortality ratio is 6.5–
7.9 times greater than for individuals in the general population (ERA-EDTA annual report, 
2011; USRDS annual data report, 2013). Age- and gender adjusted mortality in dialysis 
patients is almost two-fold higher than in patients with cancer or chronic heart failure 
illustrating the severity of ESRD (USRDS annual data report, 2013). Survival of kidney 
transplant recipients is better with five-year survival of 85–94%, but adjusted mortality ratio 
is still 1.0–1.5 times as high as in the general population (ERA-EDTA annual report, 2011; 
USRDS annual data report, 2013). 
Cardiovascular causes of death are the most common among ESRD patients, being the cause 
of death in approximately half of the cases. Infections are the cause of death in a quarter of the 
patients, and cancer, or disease that caused kidney failure both in less than 10% of the ESRD 
patients (Finnish Registry for Kidney Diseases, Report 2008). Although cardiovascular 
mortality is 10–20 times higher in dialysis patients than in the general population, 
noncardiovascular mortality is equally increased. Consequently, increased mortality is not 
caused by excess cardiovascular mortality alone (de Jager, et al., 2009).   
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2.3.2 Risk factors 
 
Most of the risk factors affecting survival of patients on RRT are similar to those of 
individuals in the general population. However, there are differences and the magnitude of the 
influence of risk factors may differ. 
Age at the start of RRT is one of the most important mortality risk factors (Postorino, et al., 
2009; Van Mannen, et al., 2007), but gender seems to have no effect on survival in ESRD 
patients in contrast to the general population (Villar, et al., 2007; Wallen, et al., 2001). 
Comorbidities and their severity increase mortality among these patients (Khan, et al., 1993; 
Lucas, et al., 2003; Miskulin, et al., 2003). Patients with ESRD and diabetes have worse 
survival than other patients on RRT (Foley, et al., 1997; Lok, et al., 2004; Postorino, et al., 
2009; van Mannen, et al., 2007; Wallen, et al., 2001). No survival difference between patients 
with diabetes as the cause of renal disease and as a comorbid condition have been found 
(Schroijen, et al., 2011). Cardiovascular disease is the most common cause of death in ESRD 
patients, and understandably the presence of cardiovascular disease is associated with higher 
mortality (Mailloux, et al., 1996; van Mannen, et al., 2007). Heart failure (Foley, et al., 1997), 
left ventricular hypertrophy (Stack, et al., 2002), cancer, cerebrovascular disease, peripheral 
artery disease (Ono, et al., 2003; van Mannen, et al., 2007), hypertension (Lucas, et al., 2003; 
Mailloux, et al., 1996), and low BMI (Postorino, et al., 2009) have also been shown to 
associate with increased mortality among ESRD patients. 
Biochemical variables can also be used to estimate mortality risk among these patients. 
Hypoalbuminemia reflects poor nutritional status, liver malfunction, excessive proteinuria, 
inflammation, fluid retention, and overall morbidity. Consequently, hypoalbuminemia is a 
strong predictor of death among ESRD patients (Culp, et al., 1996; Lackson, et al., 2009; 
Mailloux, et al., 1996). ESRD usually causes anemia and is treated with erythropoiesis-
stimulating agents. Better survival has been shown to associate with higher hemoglobin level 
(Avram, et al., 2003; Lackson, et al., 2009; Locatelli, et al., 2004; Postorino, et al., 2009). 
However, correction of anemia to normal hemoglobin level in hemodialysis patients with 
cardiac disease can increase mortality (Besarab, et al., 1998). Serum phosphorus 
concentration can be used to assess efficiency of dialysis, medication, and diet. 
Hyperphosphatemia is associated with increased mortality (Covic, et al., 2009; Lackson, et al., 
2009; Trivedi, et al., 2005), but also low phosphate concentration on hemodialysis has been 
shown to predict premature death (Block, et al., 2004; Kalantar-Zadeh, et al., 2006). 
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Treatment of hyperphosphatemia with non-calcium-based phosphate binders seems to 
decrease a risk of death compared with treatment with calcium-based  phosphate binders 
(Jamal, et al., 2013). 
 
Table 4. Mortality risk factors of ESRD patients  
Study, year Country Patients Number 
of 
patients 
Reported predictors of death 
Foley, et 
al., 1997 
Canada Patients with 
diabetes and 
ESRD 
116 Age, left ventricular hypertrophy, 
smoking, coronary artery disease, 
cardiac failure, hypoalbuminemia 
Khan, et 
al., 1993 
UK Incident RRT 
patients 
375 Comorbidity 
Lacson, et 
al., 2009 
United 
States 
Hemodialysis 
patients 
78 420 The top 5 actionable variables: serum 
albumin, phosphorus, hemoglobin, 
vascular access type, equilibrated Kt/V 
Lucas, et 
al., 2003 
Spain Incident 
hemodialysis 
patients 
184 Hypertension and comorbidity  
Mailloux, 
et al., 1996 
United 
States 
ESRD 
patients 
683 Hypertension, low serum albumin and 
coronary artery disease  
Miskulin, 
et al., 2003 
United 
States 
Incident RRT 
patients 
733 Prevalence and severity of 
comorbidities  
Ono, et al., 
2003 
Japan Hemodialysis 
patients 
1010 Ankle-brachial blood pressure index as 
a sign of peripheral vascular disease 
Postorino, 
et al., 2009 
Italy ESRD 
patients 
537 Low BMI, high waist circumference, 
age, diabetes, high C reactive protein, 
and low hemoglobin  
Stack, et 
al., 2002 
United 
States 
ESRD 
patients 
2584 Left ventricular hypertrophy 
Trivedi, et 
al., 2005 
United 
States 
Peritoneal 
dialysis 
patients 
191 Phosphorus and lean body mass 
van 
Mannen, et 
al., 2007 
Austria, 
Italy, 
Spain, 
Norway, 
UK  
Incident RRT 
patients  
15 571 Age, diabetes, coronary artery disease, 
peripheral artery disease, 
cerebrovascular disease and cancer  
Wallen, et 
al., 2001 
United 
States 
ESRD 
patients 
4948 Vascular comorbidity and diabetes 
increase cardiac mortality 
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2.3.3 Improvement over time  
 
Survival of patients on RRT has improved over time. In Finland, mortality of the RRT 
patients decreased between 2002 and 2012 from 106 to 90 deaths / 1000 patient-years 
(Finnish Registry for Kidney Diseases, Report, 2012). Because the mean age of RRT patients 
has increased at the same time, age-adjusted mortality has decreased even more. Decrease in 
mortality is similar in other European countries and in the United States. Two-year adjusted 
survival in European RRT patients has increased from 79.9% in 2002–2006 to 81.6% in 
2005–2009 (ERA-EDTA annual report, 2011), and in the United States adjusted five-year 
survival among dialysis patients was 30% in 1998 and increased to 36% in 2006, and among 
patients with kidney transplant, the corresponding survival rates were 81% and 85% (USRDS 
annual data report, 2013).  
The decrease in mortality is probably the result of improvements in RRT and other factors 
related to disease treatment and public health. However, the knowledge of specific factors 
behind the improved survival is scarce.    
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AIMS OF THE STUDY 
 
Survival of patients on RRT is poor, and even worse among RRT patients with diabetes. 
Nevertheless, knowledge on survival specifically in patients with type 1 diabetes on RRT and 
factors associating with mortality are scarce and scattered. 
 
The following main aims were addressed in this study: 
 
• To investigate whether survival of patients with type 1 diabetes on RRT has improved 
over time  
• To estimate the association of comorbidities and biochemical variables with survival 
of patients with type 1 diabetes on RRT 
• To examine the changes of medication during predialysis phase and association 
between medication and survival among patients with type 1 diabetes on RRT 
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SUBJECTS, STUDY DESIGS AD METHODS 
 
1. Finnish Registry for Kidney Diseases 
 
This study is based on the data retrieved from the Finnish Registry for Kidney Diseases. This 
registry has collected information from all nephrology units about dialysis and kidney 
transplantation patients in Finland since 1964 in collaboration with the EDTA (European 
Dialysis and Transplantation Association) Registry and as an independent national registry 
since 1989 still reporting to the EDTA Registry. The Finnish Registry for Kidney Diseases 
has an estimated coverage of 97–99% of all chronic RRT patients in Finland (Finnish 
Registry for Kidney Diseases, 2012). The registry is maintained by the Finnish Kidney and 
Liver Association, and is fully financed by the National Institute of Health and Welfare. The 
registry collects information on age, sex, cause of ESRD, initial type and changes in type of 
RRT (peritoneal dialysis, hemodialysis or kidney transplantation), laboratory results, kidney 
transplantation, and cause of death. Extensive data have been collected since 2000 at start of 
RRT on the presence of coronary artery disease, peripheral artery disease, left ventricular 
hypertrophy, heart failure, cerebrovascular disease, and treatment of hypertension and 
dyslipidemia using a “tick the correct box” system. Kidney disease diagnoses causing ESRD 
have been stored in the registry according to International Classification of Diseases (ICD) -9, 
and later as ICD-10 codes. This enables separation between patients with type 1 and type 2 
diabetic nephropathy.  
All patients provided written informed consent for use of their data anonymously for research 
purposes, and therefore separate approval of an ethics committee was not needed for this 
observational study. 
 
2. Study I 
 
In Study I we observed an incident cohort including all patients with type 1 diabetes as the 
cause of CKD according to the Finnish Registry for Kidney Diseases that had entered chronic 
RRT in Finland from 1 January 1980 to 31 December 2005 (n = 1604). A total of 8719 
patients started RRT during this time period and of these, 18.4% had type 1 diabetes as the 
cause of ESRD. The patients were followed from the first dialysis treatment until death, 
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recovery of kidney function, moving abroad, lost to follow-up, or the end of the follow-up 
period (31 December 2007). Recovery of kidney function was recorded in five patients and 
four patients moved abroad. All patients with chronic glomerulonephritis, except for 
glomerulonephritis caused by systemic diseases, who had entered RRT during the same time 
period were included as a control group (n = 1556). The patients with chronic 
glomerulonephritis as the cause of ESRD were chosen to represent a primary renal disease. 
Thus, we could obtain information to be able to separate the impact of advancement in RRT 
and diabetic care.  
The diagnosis of ESRD was confirmed by kidney biopsy in 80 patients (5%) with type 1 
diabetes. This percentage is low because kidney biopsy is considered redundant in patients 
with type 1 diabetes if there are other signs of microvascular end-organ damage, such as 
diabetic retinopathy. Kidney biopsy was taken from a minimum of 980 patients (63%) with 
glomerulonephritis. The biopsy incidence increased over time from 43% to 85%.   
The study period was divided into five intervals: 1980–1984, 1985–1989, 1990–1994, 1995–
1999, and 2000–2005. The patients were further divided into four groups based on the age at 
the start of RRT: less than 35 years (444 patients), 35–44 years (586 patients), 45–54 years 
(383 patients), and 55 years or older (191 patients). Patient survival in each time interval and 
age group was investigated and compared. 
 
3. Study II    
 
A total of 4421 patients started chronic RRT in Finland from 1 January 2000 to 31 December 
2008. According to the Finnish Registry for Kidney Diseases type 1 diabetes was the cause of 
CKD in 656 (15%) patients, and these were included in Study II. The patients were monitored 
from the start of RRT until death, recovery of kidney function, loss to follow-up, moving 
abroad or until the end of the follow-up period (31 December 2008). Recovery of kidney 
function was recorded in two patients and two patients moved abroad. 
Comorbidities were reported at the start of RRT, including peripheral artery disease, coronary 
artery disease (angina pectoris, myocardial infartation, or coronary artery intervention), 
cerebrovascular disease, left ventricular hypertrophy, and heart failure. Nephrologists reported 
the prescence of comorbidity at start of RRT using a “tick the correct box” system, and the 
information on comorbidities were reported according to existing information and not 
examined for registry purposes. In order to evaluate the difference in the prevalence of 
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comorbidities between RRT patients with and without diabetes, The control group included 
all patients 18 years or older with other diseases than type 1 or type 2 diabetes as the cause of 
CKD starting RRT during the same time period (n = 2801). Data on comorbidities was 
available for 86% (left ventricular hypertrophy) to 96% (coronary artery disease) of the 
patients with type 1 diabetes, and analyzed the effect of comorbidities on survival.  
Age, gender, obesity (BMI categories), and blood pressure in addition to comorbidities, were 
included into the multivariate analysis. Only 75% of the patients presented of the required all 
needed information and could be included in the analysis. The possibility of selection bias in 
adjusted analyses was evaluated by comparison between included and excluded patients. 
 
4. Study III    
 
A total of 5782 patients started chronic RRT in Finland from 1 January 2000 to 31 December 
2011. Type 1 diabetes was the cause of CKD in 834 (14%) patients, and these were included 
in Study III. The patients were monitored from start of RRT until death or the end of the 
follow-up period (31 December 2011). Recovery of kidney function was recorded in four 
patients and three patients moved abroad. 
Reporting centers are asked to report biochemical variables before RRT start and at the end of 
each year on RRT, but individual dates of these results are not known. Biochemical values 
were measured 0–2 weeks before RRT start. Biochemical variables observed in blood or 
plasma were creatinine, albumin, urea, ionized calcium, phosphorus, hemoglobin, C-reactive 
protein, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, trigycerides, and HbA1c. Values were recorded in SI units. Data on 
biochemical variables were available from 80% (LDL-cholesterol) to 99% (creatinine) of the 
patients. The association between biochemical variables and survival on RRT was evaluated.   
 
5. Study IV 
 
According to the Finnish Registry for Kidney Diseases 509 patients with type 1 diabetes as 
the cause of CKD initiated chronic RRT in Finland from 1 January 2000 to 31 December 
2006. In Study IV, 496 of these patients who were classified as having type 1 diabetes were 
also included in the FinDM II study (Sund, et al., 2009). The patients were followed until 
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death, recovery of renal function, loss to follow-up, moving abroad, or to the end of follow-up 
(31 December 2009). Recovery of kidney function was recorded in two patients and two 
patients moved abroad. The FinDM II study has collected information on diabetes patients in 
Finland from several national health registries including the Finnish Prescription Register 
maintained by the Social Insurance Institution. That data was used to collect information on 
medication of these patients.  
The Finnish Prescription Register has information on all reimbursed drug purchases for 
Finnish residents since 1994 (Klaukka, 2001). Drug purchases of these patients was recorded 
in four-month-periods, because patients can receive medication from a pharmacy for a 
maximum of three months’ use at a time. Observed time intervals were 0 to 4 months, 12 to 
16 months, and 32 to 36 months before, and 0 to 4 months after the RRT start. The use of 
angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), 
calcium channel blockers (CCBs), beta-blockers (BBs), statins, vitamin D (alfacalcidol, 
paricalcitol, or dihydrotachysterol), erythropoiesis-stimulating agents (ESAs), and phosphate 
binders was monitored. Before RRT start, all of the patients using phosphate binders used a 
calcium-based regimen. After RRT start, six patients began to use a non-calcium-based 
phosphate binder (sevelamer or lanthanum carbonate). To evaluate the association of 
medication utilization before RRT start and survival, data on drug purchases during the last 
four months before RRT start was used.    
 
6. Statistical analyses 
 
Differences in variable distributions between patient groups were assessed using the chi-
square test for categorical variables and the Mann-Whitney-U test for continuous variables. 
Logistic regression was used for adjusted comparison of comorbidity prevalences between 
patient groups. Median survival times were estimated from the Kaplan-Meier curves, and 
differences in survival probabilities between groups were assessed using the log-rank test. 
Relative risks of death as a function of explanatory variables were estimated using Cox 
proportional hazards regression, with death as the event and censoring at last date of follow-
up. Censoring was not performed at time of kidney transplantation. Proportionality 
assumptions of the Cox regression models were tested by visual inspection of Kaplan-Meier 
suvival curves according to quintiles of laboratory variables. Cox proportional hazards 
regression was used to perform multivariable modelling of survival probabilities and for 
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adjustment of potential confounding factors. Two-sided P values lower than 0.05 were 
considered statistically significant. Interactions between the explanatory variables were 
considered by including interaction terms in Cox regression model. Interaction means that the 
effect of one variable on survival differs according to the level of another variable. When 
analyzing multiple interactions, Bonferroni adjustment was used to calculate reduced 
significance level for P value in order to decrease risk of detecting interactions simply due to 
multiple testing, and interaction was considered significant if the two-sided P value was lower 
than 0.001. For statistical analyses, SPSS Statistics versions 16.0, 17.0, 20.0 and STATA 12.1 
were used. 
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RESULTS 
1. Baseline characteristics 
 
Baseline characteristics of the study cohorts are described in Table 5. Median age was 42–45 
years at the time of RRT initiation, and two thirds of the patients were male. Hemodialysis 
and peritoneal dialysis were almost equally often chosen as the first treatment modality. 
Cardiovascular disease was the cause of death in two thirds of the patients.  
 
Table 5. Baseline characteristics 
 Study I Study II Study III Study IV 
Patients (n) 1604 656 834 496 
Median age at RRT start (years) 42.3 44.7 45.7 43.9 
Males (%) 63.8 64.3 63.9 64.9 
Median follow-up (years) 4.2 2.9 3.7 4.6 
Loss to follow-up (n) 4 4 7 4 
Primary treatment modality     
-Hemodialysis (%) 46.1 53.2 54.1 52.0 
-Peritoneal dialysis (%) 53.5 46.8 45.9 48.0 
-Pre-empitive transplantation (%) 0.4 0 0 0 
Renal transplantation during follow-up (%) 54.1 39.3 42.6 51.4 
Time on dialysis before transplantation (years) 1.3 1.5 1.4 1.4 
Cause of death     
-Cardiovascular (%) 65.8 65.9 65.1 68.9 
-Infection (%) 17.1 13.6 15.1 13.1 
 
2. Study I: Survival of patients with type 1 diabetes receiving renal 
replacement therapy in 1980–2007 
 
Survival of patients with type 1 diabetes 
Of the 1604 patients with type 1 diabetes, 1047 (65.3%) died during the follow-up. Median 
survival time increased markedly over time. When RRT started in the periods 1980–1984 and 
1995–1999 were compared, median survival time increased from 3.60 years (95% CI 2.50–
4.70) to 7.24 years (95% CI 5.74–8.74) (Figure 7). Median survival time of patients starting 
RRT during 2000–2005 was longer than the maximal follow-up time (8 years), and therefore 
could not be calculated.  
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Figure 7. Survival of patients with type 1 diabetes on RRT according to RRT starting periods 
 
 
Survival improved similarly in all of the age groups. Five-year mortality from the start of 
RRT decreased from 51% in 1980–1984 to 33% in 2000–2005. The unadjusted relative risk 
of death decreased 45% when patients that entered RRT in 1980–1984 and 2000–2005 were 
compared (Table 6). Because age at start of RRT is a significant predictor of survival and 
median age at start of RRT increased significantly during our study period, corresponding 
relative risks of death decreased even more in age groups varying between 62% and 69%. 
Without adjustments, the risk of death increased by 4.1% (95% CI 3.4–4.7%) per year of age 
at the start of RRT, and hemodialysis as the initial mode of RRT was associated with 1.4-fold 
risk (95% CI 1.2–1.6) of death compared to peritoneal dialysis. Relative risk of death was 
significantly higher in patients who did not receive renal transplantation within 2 years from 
the RRT start compared to those who did (RR 4.0, 95% CI 3.5–4.6). Gender was not 
associated with risk of death. 
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Adjusted survival of patients with type 1 diabetes 
When adjusted for age and sex, survival improved more prominently, with relative risk of 
death of 0.33 for patients with type 1 diabetes entering RRT in 2000–2005 compared to 1980–
1984. When initial mode of dialysis and having or not having received a kidney transplant 
within 2 years from the start of RRT were added in to a multivariate model, the relative risk of 
death decreased even more markedly to 0.23 (Table 6). Decrease in the relative risk of death 
was similar in patients who received a kidney transplant (RR 0.20, 95% CI 0.11–0.37) and in 
those who did not (RR 0.25, 95% CI 0.19–0.33). 
 
Table 6. Survival according to the start period of renal replacement therapy among patients 
with type 1 diabetes and patients with glomerulonephritis 
Type 1 diabetes 1980–1984 1985–1989 1990–1994 1995–1999 2000–2005 
5-year survival (%) 49 55 59 62  67 
Unadjusted RR 1 0.87      0.70      0.66      0.55      
(95% CI)  (0.72–1.06) (0.58–0.85) (0.54–0.81) (0.44–0.68) 
Adjusted RRa      1 0.72      0.53      0.43      0.33      
(95% CI)  (0.59–0.87) (0.44–0.65) (0.35–0.52) (0.26–0.41) 
Adjusted RRb   1 0.64      0.44      0.33      0.23      
(95% CI)  (0.52–0.77) (0.36–0.54) (0.27–0.41) (0.19–0.29) 
Glomerulonephritis 1980–1984 1985–1989 1990–1994 1995–1999 2000–2005 
5-year survival (%) 77 75 67 69 77 
Unadjusted RR 1 1.01 1.21 1.17 0.88 
(95% CI)  (0.82–1.25) (0.98–1.50) (0.93–1.46) (0.68–1.14) 
Adjusted RRa      1 0.86 0.72 0.59 0.37 
(95% CI)  (0.69–1.06) (0.58–0.90) (0.47–0.74) (0.28–0.49) 
Adjusted RRb   1 0.76 0.60 0.49 0.30 
(95% CI)  (0.61–0.94) (0.48–0.75) (0.38–0.62) (0.23–0.40) 
RR, Relative risk of death; 95% CI, 95% Confidence interval 
aAdjusted for age at start of RRT and sex  
bAdjusted for age at start of RRT, sex, initial mode of dialysis, and having or not having 
received a kidney transplant within two years of the RRT start 
 
Comparison between patients with type 1 diabetes and glomerulonephritis 
There were 823 (52.9%) deaths among patients with glomerulonephritis, and 733 patients 
were censored. Of the censored patients, 719 were alive on 31 December 2007, eight regained 
own kidney function, four moved abroad, and two were lost to follow-up. Hemodialysis was 
the initial RRT mode in 64.8%, peritoneal dialysis in 33.9%, and pre-emptive kidney 
transplantation in 1.2% of the patients. The patients with glomerulonephritis had significantly 
higher median survival time than that of patients with type 1 diabetes. However, it did not 
increase significantly during the follow-up (median survival time was 11.50 years). The 
unadjusted relative risk of death (RR = 0.88) improved markedly after adjustment for other 
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variables (RR = 0.30) in patients entering RRT in 2000–2005 compared to 1980–1984 (Table 
6). Interaction analysis between ESRD diagnosis (type 1 diabetes and glomerulonephritis) and 
the RRT start period with adjustment for age, gender, treatment mode, and kidney transplant 
status at 2 years indicated a greater decrease in the risk of death among patients with type 1 
diabetes than patients with glomerulonephritis (P = 0.007). The risk of death for patients with 
type 1 diabetes compared to patients with glomerulonephritis on RRT was 3.5-fold during 
1980–1984, but decreased to 2.7-fold during 2000–2005. 
 
Interaction analysis 
There were no statistically significant first or second degree interactions in patients with type 
1 diabetes between the variables RRT start period, age at start of RRT, gender, initial mode of 
dialysis, and having or having not received a kidney transplant within 2 years from the RRT 
start. 
 
3. Study II: Comorbidities and survival of patients with type 1 diabetes on 
renal replacement therapy 
 
Prevalence of comorbidities, obesity, and medication for hypertension and dyslipidemia  
Patients with type 1 diabetes had high prevalence of comorbidities with an average of 1.2 
comorbidity per patient, and 52% of the patients had at least one comorbidity. The most 
common comorbidities were left ventricular hypertrophy, coronary artery disease, and 
peripheral artery disease (Figure 8).  
Comorbidities, especially peripheral artery disease, were more common in patients with type 
1 diabetes than in patients without diabetes, and patients with type 1 diabetes more often used 
medication for dyslipidemia and hypertension. The mean age at RRT start was 15 years lower 
among the patients with type 1 diabetes, and therefore after adjustment for age and sex the 
probability for having a comorbidity or medication (Figure 8) was significantly higher (P < 
0.05) in all observed variables except for diastolic blood pressure and obesity.  
 
 
 
 
 
 44 
Figure 8.  Prevalence of comorbidities in patients with type 1 diabetes on RRT 
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Effect of comorbidities on risk of death  
Of the patients, 209 died during follow-up. All observed comorbidities were associated with 
increased risk of death in a univariate model. After adjustment for age and sex, heart failure 
was associated with the highest risk of death, but the association of invasively treated 
coronary artery disease and high diastolic blood pressure with survival disappeared (Table 7).  
When all variables listed in Table 4 were analyzed in the multivariate model, independent 
predictors of death were age at start of RRT, peripheral artery disease, left ventricular 
hypertrophy, and heart failure. 
The information on comorbidities was incomplete for 24.7% of the patients with type 1 
diabetes, and these patients were excluded from the multivariate analysis. Survival between 
included and excluded patients was, however, similar. Furthermore, addition of initial 
treatment modality into the multivariate model did not change the results. 
 
6umber of comorbidities and risk of death  
Increasing the number of comorbidities increased the risk of death. After adjustment for age 
and sex, the patients with more than two comorbidities, compared to the patients without 
comorbidities, had a 3.6-fold risk of death (Table 8). Median survival time was 7.0 years with 
one, 4.4 years with two, and 2.7 years with three or more comorbidities. The median survival 
time was over 9 years if there was no comorbidity (Figure 9). 
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Table 7. Effect of comorbidities on risk of death among patients with type 1 diabetes on RRT 
Unadjusted Adjustedª Adjustedb  
RR (95% CI) RR (95% CI) RR (95% CI) 
Heart failure 4.87 (3.21–7.38) 3.25 (2.10–5.03) 2.50 (1.32–4.59) 
Peripheral vascular disease 2.92 (2.16–3.94) 2.31 (1.69–3.14) 1.88 (1.25–2.83) 
Left ventricular hypertrophy 1.75 (1.29–2.38) 1.76 (1.30–2.39) 1.68 (1.18–2.40) 
Age at start (per 10-year increment) 1.62 (1.43–1.85) 1.63 (1.43–1.85) 1.41 (1.15–1.72) 
Coronary artery disease    
-No disease 1 1 1 
-Non-invasively treated 2.09 (1.42–3.07) 1.63 (1.10–2.42) 1.32 (0.78–2.22) 
-Invasively treated 1.56 (1.05–2.30) 1.01 (0.67–1.52) 0.65 (0.37–1.14) 
Cerebrovascular disease 2.18 (1.51–2.30) 1.63 (1.11–2.38) 1.25 (0.76–2.05) 
Body mass index    
-20–30 1 1 1 
-<20 1.67 (1.00–2.79) 1.56 (0.93–2.62) 1.59 (0.84–3.00) 
->30 1.02 (0.66–1.55) 0.92 (0.60–1.40) 0.82 (0.49–1.36) 
Female gender 1.07 (0.81–1.43) 1.15 (0.86–1.52) 1.29 (0.91–1.84) 
Systolic blood pressure (per 10 mmHg) 0.98 (0.93–1.04) 0.99 (0.94–1.05) 0.98 (0.89–1.08) 
Diastolic blood pressure (per 10 mmHg) 0.85 (0.76–0.95) 1.00 (0.89–1.13) 1.02 (0.84–1.24) 
RR, relative risk of death; 95% CI, 95% confidence interval 
ª Age- and sex-adjusted 
b  Multivariate model of all variables 
 
Table 8. Number of comorbidities and risk of death among patients with type 1 diabetes on 
RRT 
Number of comorbidities Unadjusted Adjustedª 
 RR (95% CI) RR (95% CI) 
0 1 1 
1 1.96 (1.38–2.79) 1.78 (1.25–2.54) 
2 3.05 (2.05–4.53) 2.40 (1.59–3.62) 
3 or more 5.18 (3.38–7.93) 3.65 (2.33–5.70) 
RR, relative risk of death; 95% CI, 95% confidence interval 
ª Age-, and sex-adjusted 
 
The risk of death was 39% after five years on RRT for all patients with type 1 diabetes, but 
only 26% in those without comorbidities. Hereby, the population-attributable risk was 33% 
[(0.39–0.26)/0.39]. It indicates that one third of the deaths could be attributed to comorbidities. 
The estimate was similar after adjustment for age and sex. 
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Figure 9. Survival probability of patients with type 1 diabetes starting RRT 
according to number of comorbidities.  
 
 
 
Interaction analysis  
No statistically significant interactions were observed between comorbidities, blood pressure, 
BMI, sex, and age at start of RRT. 
 
4. Study III: Biochemical variables and survival of patients with type 1 
diabetes on renal replacement therapy 
 
Association of biochemical variables and survival  
Of the patients, 313 died during follow-up. When we analyzed association of biochemical 
variables and mortality without adjustment, significant predictors of worse survival were 
lower creatinine and albumin and increased C-reactive protein concentrations. When adjusted 
for age and sex, low hemoglobin was also associated with higher mortality in addition to the 
above-mentioned variables (Table 9). Of the patients, 82% used erythropoiesis-stimulating 
agents. The use of erythropoiesis-stimulating agents did not have an effect on relative risk of 
death associated with hemoglobin concentration.  
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Table 9. Biochemical variables before entering RRT and associated risks of death in patients 
with type 1 diabetes on RRT 
 Median Unadjusted Adjusteda 
 value RR 95% CI RR 95% CI 
Creatinine (per 100 umol/l) 558 0.86c 0.81–0.91 0.88c 0.83–0.94 
Albumin (per 5 g/l) 32.0 0.84c 0.77–0.91 0.79c 0.73–0.87 
Hemoglobin (per 10 g/l) 109 0.94 0.88–1.01 0.93b 0.86–1.00 
C-reactive protein (per 10 mg/l) 5.0 1.04b 1.01–1.07 1.04b 1.01–1.07 
HbA1C (%) 8.3 1.04 0.97–1.11 1.07 1.00–1.15 
Phosphorus (mmol/l) 1.84 0.89 0.73–1.09 1.03 0.83–1.27 
Urea (per 10 mmol/l) 27.1 1.09 0.95–1.24 1.01 0.88–1.16 
Calcium-ion (mmol/l) 1.16 0.70 0.26–1.86 0.45 0.17–1.22 
Cholesterol (mmol/l) 4.15 0.91 0.82–1.02 0.94 0.84–1.04 
HDL-cholesterol (mmol/l) 1.22 0.87 0.67–1.13 0.78 0.59–1.03 
Triglycerides (mmol/l) 1.43 0.92 0.80–1.06 0.94 0.82–1.09 
LDL-cholesterol (mmol/l) 2.09 0.91 0.80–1.05 0.96 0.84–1.10 
RR, relative risk of death per one unit increase of value; 95% CI, 95% confidence interval 
ªAge- and sex-adjusted 
b
P < 0.05 
c
P < 0.001 
 
Because comorbidities are significant predictors of death, and may associate with biochemical 
values and their medical treatment, a multivariate adjustment for comorbidities (coronary 
artery disease, peripheral vascular disease, left ventricular hypertrophy, heart failure and 
cerebrovascular disease), age, sex, and initial treatment modality of RRT was performed. 
After this adjustment, independent predictors of mortality were lower creatinine, and albumin, 
and increased C-reactive protein.  
Figure 10 shows how categorizing by age at RRT start, presence of comorbidity, and 
predialytic albumin level helps to detect patients with high risk of death. 
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Figure 10. Effect of age at RRT start, comorbidity status, and albumin level on survival 
 
 
 
Alb, albumin (g/l) measured 0–2 weeks before RRT start 
 
 
5. Study IV: Medication during predialysis phase and survival of patients with 
type 1 diabetes on renal replacement therapy 
 
Prevalence of medication 
Of the 496 patients, the most frequently used medications before RRT start were CCBs (69%), 
BBs (68%), and ACEIs or ARBs (63%). Predialytic use of all groups of medication became 
more common when start of RRT was approaching except for ACEIs (Figure 11). After 
initiation of RRT, use of other than antihypertensive medication increased. Patients with 
cardiovascular comorbidities more often used statins, BBs, and vitamin D, whereas the 
utilization of CCBs was less frequent in patients with cardiac problems (Table 10). Higher 
concentrations of serum albumin were associated with the use of vitamin D and/or phosphate 
binders. 
No comorbidity Comorbidity 
Type 1 diabetes 
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Figure 11. Prevalence of drug utilization 
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Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker; CCB, calcium channel blocker; BB, beta-blocker; Vit D, vitamin D; ESA, 
erythropoiesis-stimulating agent; PhosB, phosphate binder 
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Table 10. Patient characteristics and drug utilization 0 to 4 months before RRT start 
 Use of 
drug 
Number 
of 
patients 
Male 
(%) 
PAD 
(%) 
CAD 
(%) 
HF    
(%) 
CVD 
(%) 
LVH 
(%) 
ACEI yes 195 61.5 12.1 20.1 4.1 9.9 27.3 
 no 301 67.1 23.0 21.4 6.4 10.0 31.3 
ARB yes 138 65.9 19.5 20.9 7.0 6.3 29.4 
 no 358 64.5 18.5 20.7 5.0 11.3 29.8 
CCB yes 344 67.4 16.6 18.3 3.2 10.0 29.5 
 no 152 59.2 18.3 26.7 10.7 9.9 30.2 
Statin yes 268 65.3 24.1 29.3 5.7 11.9 33.0 
 no 228 64.5 12.3 10.7 5.4 7.7 25.8 
BB yes 337 67.4 19.6 24.8 6.6 10.3 32.3 
 no 159 59.7 17.1 12.8 3.4 9.2 24.5 
Vitamin D yes 181 64.1 19.2 26.7 6.1 10.1 28.3 
 no 315 65.4 18.5 17.5 5.3 9.9 30.6 
ESA yes 267 58.8 20.6 18.8 6.2 10.8 25.4 
 no 229 72.1 16.7 23.3 4.8 8.9 34.7 
PhosB yes 219 65.8 17.9 22.1 6.4 6.4 27.2 
 no 277 64.3 19.5 19.9 4.9 12.7 31.8 
All  496 64.9 18.8 20.9 5.6 10.0 29.7 
 
 Use of 
drug 
Number of  
patients 
Age at 
RRT start 
(years) 
BMI  
(kg/m2) 
Syst BP 
(mmHg) 
Albumin  
(g/l) 
ACEI yes 195 43.2 24.0 155 32.0 
 no 301 44.4 24.5 156 32.0 
ARB yes 138 43.3 24.5 160 32.0 
 no 358 44.1 24.2 154 32.0 
CCB yes 344 44.3 24.5 158 32.0 
 no 152 42.6 24.1 150 31.0 
Statin yes 268 45.9 24.9 156 32.0 
 no 228 41.3 23.7 156 31.3 
BB yes 337 44.7 24.8 157 32.0 
 no 159 42.3 23.6 151 31.0 
Vitamin 
D 
yes 181 47.4 23.8 153 33.0 
 no 315 42.3 24.5 157 31.5 
ESA yes 267 44.9 23.7 156 32.0 
 no 229 42.8 24.9 155 32.0 
PhosB yes 219 44.8 24.6 158 33.0 
 no 277 43.2 24.3 150 31.0 
All  496 43.9 24.4 156 32.0 
PAD, peripheral artery disease; CAD, coronary artery disease; HF, heart failure; CVD, 
cerebrovascular disease; LVH, left ventricular hypertrophy; Syst BP, systolic blood pressure; ACEI, 
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel 
blocker; BB, beta-blocker; ESA, erythropoiesis-stimulating agent; PhosB, phosphate binder; All, 
values for all of the patients 
Median values are reported for continuous variables 
Bolded, statistically significanct difference (P < 0.05) 
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Association between medication and intermediate markers 
Ninety percent (N=445) of the patients used antihypertensive medication before RRT start. 
Median systolic blood pressure was 156 mmHg and diastolic blood pressure 85 mmHg in 
patients with antihypertensive medication compared with 145 mmHg and 87 mmHg, 
respectively, in patients without antihypertensive medication. Hemoglobin level was higher 
among users of ESAs (113 vs. 105 g/l, P<0.001), and low density lipoprotein (LDL) 
cholesterol concentration was lower among statin users, although without statistical 
significance (2.07 vs. 2.29 mmol/l, P=0.07). Use of vitamin D was not associated with ionized 
calcium (1.17 vs. 1.17 mmol/l, P=0.57) or phosphate (1.80 vs. 1.85 mmol/l, P=0.22) 
concentration. Concentration of ionized calcium was higher among users of phosphate binders 
(1.18 vs. 1.16 mmol/l, P=0.002), but, suprisingly, the use of phosphate binders did not 
associate with phosphate concentration (1.80 vs. 1.86 mmol/l, P=0.20). 
When exploring these associations after adjustment for age, gender, albumin, systolic blood 
pressure, body mass index (BMI), and comorbidities, the use of ESAs correlated with higher 
hemoglobin concentration. However, systolic or diastolic blood pressure between users and 
non-users of antihypertensive drugs, phosphate concentration between users and non-users of 
phosphate binders, and LDL-cholesterol concentration between statin users and non-users did 
not differ significantly.  
 
Association between medication and survival  
Of the patients, 206 died during follow-up. When evaluated without adjustment, the use of 
CCBs during four months before the start of RRT was the only medication associating with 
survival, and showed 29% reduction in risk of death. The results for use of CCBs remained 
unchanged after adjustment for age and sex. Moreover, the use of vitamin D was associated 
with a 30% decrease in the risk of death (Table 11). 
After adjustment for age, sex, comorbidities (coronary artery disease, peripheral artery disease, 
left ventricular hypertrophy, heart failure, and cerebrovascular disease), body mass index, and 
serum albumin, no associations were found between the use of medication and mortality 
(Table 12). When analyzing separately in patients with and without comorbidities as 
subgroups, or if the use of ACEIs and ARBs were combined, the results remained similar. 
Adding information on renal transplantation status did not have an effect on the results either. 
The association of medication use 0 to 4 months after RRT start and survival in this 
multivariate model was also assessed. Better survival was associated with the use of vitamin 
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D (RR 0.63, 95% CI 0.44–0.92). Otherwise the results were similar to those reported 
regarding medicine use before RRT start.   
 
Table 11. Medication before RRT start and relative risk of death 
 Unadjusted Age- and sex-adjusted 
 RR 95% CI RR 95% CI 
Antihypertensive drug 0.79 0.51–1.23 0.78 0.50–1.21 
 -ACEI 0.79 0.59–1.05 0.79 0.59–1.05 
 -ARB 0.98 0.72–1.34 0.98 0.72–1.33 
 -CCB 0.71 0.54–0.95 0.71 0.53–0.95 
 -BB 1.01 0.76–1.36 0.99 0.75–1.34 
Statin 1.14 0.86–1.50 0.97 0.73–1.28 
Vitamin D 0.82 0.61–1.09 0.70 0.52–0.94 
Erythropoietin 0.93 0.70–1.22 0.86 0.65–1.14 
Phosphate binder 0.82 0.62–1.08 0.82 0.62–1.08 
Drug utilization was recorded if patient purchased drug 0 to 4 months before start of RRT 
Antihypertensive drug = use of ACEI, ARB, CCB, and/or beta-blocker  
RR, relative risk of death; 95% CI, 95% confidence interval  
Bolded, P < 0.05 
 
Table 12. Medication and risk of death after multivariable adjustment 
 RR CI 95% 
Antihypertensive drug 1.02 0.60–1.73 
 -ACEI 0.91 0.65–1.28 
 -ARB 1.16 0.81–1.65 
 -CCB 0.91 0.64–1.30 
 -BB 1.01 0.71–1.44 
Statin 0.95 0.67–1.34 
Vitamin D 0.88 0.63–1.24 
Erythropoietin 0.93 0.66–1.31 
Phosphate binder 1.10 0.79–1.53 
Drug utilization was recorded if patient purchased drug 0 to 4 months before start of RRT 
Relative risk of death was adjusted in multivariate model for age, sex, coronary artery disease, 
peripheral artery disease, left ventricular hypertrophy, heart failure, cerebrovascular disease, 
body mass index, and serum albumin 
Antihypertensive drug = use of ACEI, ARB, CCB, and/or BB 
RR, relative risk of death; 95% CI, 95% confidence interval 
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DISCUSSIO 
1. Results from this study 
 
Improved survival 
In Study I we showed a considerably improved survival of patients with type 1 diabetes on 
RRT throughout the follow-up period 1980–2007. It is worth noting that survival improved 
despite the increasing median age at start of RRT, and the declining probability to receive a 
kidney transplant. These transitions should change the prognosis in an unfavorable direction. 
However, patients´ age at the time of type 1 diabetes diagnosis has not changed, but the time 
from diagnosis to ESRD has increased (Finne, et al., 2005). When the patients with 
glomerulonephritis as the cause of CKD, excluding patients with systemic disease, were 
compared to the patients with type 1 diabetes, a more substantial survival benefit over time 
was found for diabetes patients. This indicates advances in diabetes care and management of 
diabetic complications in addition to developments in overall management of the patients with 
chronic renal disease.  
During the study period, management of diabetes has developed markedly. New insulin 
regimens have been developed and multiple insulin injections have led to more stable blood 
glucose control. Blood glucose measurements at home have become mainstay, and follow-up 
of glycosylated hemoglobin has enabled better long-term glucose control. These 
improvements most likely explain part of the observed improvement of survival in this study.  
On the other hand, dialysis therapy has also improved over the years. At the beginning of this 
study period hemodialysis patients were treated with low-flux hemodialysis, but during the 
last decades hemodiafiltration and modern high-flux dialyzers with better biocompatibility 
have become available enhancing better uremic toxin clearance and flexibility of 
hemodialysis treatment. Furthermore, the weekly hemodialysis time has increased. In this 
study of patients with type 1 diabetes, the mean number of weekly hemodialysis treatment 
hours increased from 11.4 (95% CI 10.9–12.0) in 1992 to 13.5 (95% CI 12.8–14.2) in 2007. 
On peritoneal dialysis therapy the improvement of fluids with better tolerability, solute 
removal, and ultrafiltration capability have increased efficacy. In addition, the use of 
automated overnight peritoneal dialysis machines has increased, leading to greater toxin 
clearance, better adjustment of peritoneal dialysis to everyday life with improved compliance 
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to therapy, and possibly to a decrease in peritonitis episodes (Nessim, et al., 2009; 
Rabindranath, et al., 2007). The use of an automated machine as an initial peritoneal dialysis 
treatment rose from 2% in 1992 to 27% in 2007 in this study population. Since better uremic 
toxin clearance improves survival in patients on dialysis (National Kidney Foundation, 2006), 
the improvement of dialysis techniques and increase in dialysis dose could have led to 
improved survival in this study population.  
This study indicates that both management of type 1 diabetes and development in RRT have 
led to improved survival of these patients.  
 
Comorbidities and survival 
In Study II comorbidities were shown to be common among patients with type 1 diabetes at 
the time that they entered RRT during 2000–2008 in Finland, and these comorbidities 
correlate with increased risk of death. All observed comorbidities associated with lower 
probability of survival, and after adjustment for confounding factors, peripheral artery disease, 
left ventricular hypertrophy, and heart failure remained independent predictors of death. The 
risk of death increased with growing number of comorbidities, and patients with one or more 
comorbidities compared to patients without comorbidities had more than twofold risk of death. 
Moreover, the prevalence of comorbidities, particulary peripheral artery disease, was higher 
in patients with type 1 diabetes compared to patients without diabetes on RRT.  
No information about severity or underlying cause of comorbidities was available. This makes 
it more challenging to estimate the role of comorbidities to mortality. Heart failure was 
associated with the highest increase in the risk of death. Patients with heart failure without 
ESRD have poor prognosis (Harjola, et al., 2010; Salpeter, et al., 2012), and it is not 
surprising that combination of these two severe conditions predict low life expectancy. 
Another strong independent predictor of death was peripheral artery disease, which often 
causes infectious problems to the patients. No information about the presence of infections 
was available, but infection was not a more common cause of death among patients with 
peripheral artery disease than without. However, infections may have potentiated the risk of 
death among patients with peripheral artery disease. Patients with peripheral artery disease 
often also have vascular disease in heart and brain, which could increase mortality. Of the 
comorbidities, left ventricular hypertrophy was the most common independent predictor of 
death with prevalence in one third of the patients. Therefore it is important to identify and 
treat early factors that lead to left ventricular hypertrophy, such as hypertension. The 
prevalence of prescribed blood pressure-lowering drugs was high, but most of the patients had 
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hypertension prior to start of RRT. However, monitored blood pressure was a single 
observation, and may not represent long-term blood pressure level. Because blood pressure 
was measured just before RRT start, fluid retention can cause elevation of blood pressure.  
 
Biochemical variables and survival 
In Study III, before start of chronic RRT, independent predictors of death among patients with 
type 1 diabetes included lower creatinine and albumin, and increased C-reactive protein. Low 
hemoglobin was also associated with poor survival. However, the prevalence of comorbidities 
was higher among patients with low hemoglobin concentration and may explain this result. 
Creatinine and albumin can be used to assess nutritional status, and malnutrition often 
correlates with more severe comorbidity and mortality. Creatinine concentration also reflects 
muscle mass and low creatinine associates with frailty and general morbidity. Other causes of 
hypoalbuminemia are substantial proteinuria, impaired food absorption, and liver malfunction. 
Therefore our results suggest that improvement of nutritional status and treatment of other 
possible causes of hypoalbuminemia might reduce mortality. Diagnosis and efficient 
treatment of ongoing inflammatory process also seems to be important.  
 
Medication during predialysis phase and survival 
In Study IV, in patients with type 1 diabetes, the use of medication becomes more frequent 
during the predialysis phase of renal disease. Before RRT start, over half of these patients use 
ACEIs or ARBs, CCBs, statins, BBs, or ESAs. Although after adjustment for age and sex 
there was an association between the utilization of CCBs or vitamin D before RRT start and 
lower mortality, the association dissappeared after further adjustment for confounding factors. 
Survival prognosis appears similar among patients with and without medication. 
Results confirmed that the use of medication is abundant in patients with type 1 diabetes 
during predialytic stage of renal disease. Still, the evidence on the effect of specific 
medication on survival is scarce in all ESRD patients and almost nonexisting in patients with 
type 1 diabetes. The use of antihypertensive medication becomes more frequent during the 
predialysis phase, and the use of ACEIs shifts to the use of CCBs, probably because of 
increase in potassium and creatinine concentrations. Despite the abundant use of 
antihypertensive medication, blood pressure was high among these patients. Because BBs 
block the activated adrenergic system in CKD and cardiovascular mortality is high in ESRD 
patients, the use of BBs could be beneficial for these patients. There are, however, factors that 
limit the use of BBs: fear of hypotension and bradycardia, suppressed sensation of 
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hypoglycemia in patients with diabetes, and lack of research evidence. Because CCBs do not 
dialyzate or excrete through kidneys and hereby dosing needs no alterations in CKD, they are 
commonly used for hypertension and angina pectoris in ESRD patients. ACEIs and ARBs are 
recommended during the predialysis phase in patients with diabetes as they slow down the 
progression of diabetic nephropathy and albuminuria (Brenner, et al., 2001; Kshirsagar, et al., 
2000; Lewis, et al., 2001). Because cardiovascular morbidity and mortality is high among 
these patients, the use of statins seems justifiable. The use of statins is frequent and LDL-
cholesterol levels are acceptable. However, the observed increase in the use of statins during 
the last three years before RRT initiation, raises the question whether more aggressive 
treatment of hyperlipidemia at earlier stages of diabetic nephropathy would decrease 
morbidity and mortality on cardiovascular disease. CKD disturbs vitamin D and bone 
metabolism, and this accelerates arterial calcification. A significant association was found for 
the use of vitamin D after RRT start and lower mortality, and therefore correction of vitamin 
D deficiency may be beneficial for these patients. Due to confounding by indication it is 
difficult to assess effects of medication in an observational study. However, a very large 
beneficial or adverse effect on survival does not appear likely for any of the drugs 
investigated. Use of medication seems to keep patients in most cases on a comparable survival 
level to patients not on the same medication. 
 
2. Strengths and weaknesses  
 
Knowledge on survival and the impact of factors affecting survival among patients with type 
1 diabetes on RRT is scarce and scattered. This study thus provides novel information. The 
major strengths of these studies include the virtually complete coverage of patients with type 
1 diabetes entering RRT during the entire study periods in Finland, adequate number of 
patients, sufficiently long follow-up periods, and complete information on the outcome. This 
reduces the possibility of selection bias. Furthermore, few earlier studies have been able to 
distinguish between patients with type 1 and type 2 diabetes. Data on comorbidities were 
exceptionally comprehensive and collected systematically using the same form for all patients, 
which reduces information bias. Potential influence of noncompliance could be partly 
overcome, because the information on the use of medication was based on reimbursed 
medicine purchases instead of reported prescriptions.  
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There are also some limitations in these studies. Firstly, they are observational. Therefore, no 
definitive conclusion can be made that the associations between the observed variables and 
survival are causal. This problem was addressed by adjusting for a large number of potential 
confounders. Unfortunately, for these adjustments there was no information on the severity of 
the comorbidities, and severity may well correlate with both studied factors and mortality and 
thus confound results. More reliable causal inferences could be made in randomized 
intervention trials. However, in the absence of randomized trials an observational cohort study 
gives the best evidence to evaluate the factors affecting survival and allows assessment of 
multiple potential factors in the same study. Secondly, the data on biochemical variables and 
comorbidities were unavailable for some of the patients, which reduced the proportion of the 
patients included in the multivariate analyses. This potential selection bias was estimated by 
comparing survival of patients included and excluded in these analyses. Thirdly, the results 
may not be valid in other parts of the world, as the Finnish population is almost entirely white, 
genetically quite homogenous, and the incidence of type 1 diabetes in Finland is one of the 
highest in the world (Karvonen, et al., 2000). Therefore, special attention has been directed 
towards treatment of type 1 diabetes, and that may have led to the favourable progress in 
prognosis of the Finnish patients with type 1 diabetes (Asao, et al., 2003). Potential pitfalls of 
these studies also include the differences in the characteristics of the patients with and without 
an indication to use a medication, and potential reporting bias towards more difficult cases of 
the comorbidities, as the information on comorbidities were reported according to existing 
information and not examined for registry purposes. For example, the low prevalence of 
coronary artery disease compared with an earlier study (Vilar, et al., 2007) may indicate 
underreporting of comorbidities.  
Cox proportional hazards regression models were used for adjustment of confounding factors. 
There are limitations in the use of this analysis method, because it assumes a linear 
relationship between the explanatory variable and the logarithm of the hazard ratio. It 
furthermore assumes that hazard ratio related to the predictive variable remains stable during 
time of follow-up. However, increased risk of death might be associated, for example, to both 
low and high hemoglobin values while the risk is the lowest in the middle range. Therefore, 
the explanatory variables were also explained as categories to detect these problems. Change 
in hazard ratio of death over time can be estimated by visual inspection of Kaplan-Meier 
curves. If there was significant change, Cox proportional hazards model could not be applied 
to this variable, for example, if male gender would predict increased mortality during the first 
year of follow-up, but female gender after two years. 
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3. Comparison to previous results 
 
The results presented here of the improved prognosis are in line with previous observations 
from studies exploring survival of patients with diabetes and ESRD (Sørensen, et al., 2007; 
van Dijk, et al., 2005), although Villar, et al. (2007) found no improvement in the prognosis 
of patients with type 1 diabetes on RRT 1991–2005. However, this study is the first to focus 
only on patients with type 1 diabetes and expanding the observation period to almost three 
decades.  
 
Several studies have shown that comorbidities are more common among patients with 
diabetes than among other RRT patients (Lok, et al., 2004; Stel, et al., 2005; Villar, et al., 
2007). The study by Villar and colleagues also reported the prevalence of comorbidities 
separately for patients with type 1 diabetes in New Zealand and Australia 1991–2005. They 
found markedly higher prevalence of coronary artery disease and peripheral artery disease 
than reported here. Age at start of RRT was approximately the same in both studies, and does 
not explain the observed differences. Therefore, the difference may arise from the unequal 
reporting systems or differences in the patients. 
It is a well reported fact that comorbidities increase mortality among RRT patients (Khan, et 
al., 1993; Miskulin, et al., 2003; Stack, et al., 2002; van Mannen, et al., 2007). There are only 
two small studies that have been reported on patients with diabetes on RRT estimating the 
effect of comorbidities on mortality (Foley, et al., 1997; Racki, et al., 2007). These studies 
reported increased mortality associating with heart failure, left ventricular hypertrophy, and 
coronary artery disease. However, no study has focused separately on patients with type 1 
diabetes. 
 
Among patients with type 1 diabetes but without ESRD, predictors of death include 
hyperglycemia (Rossing, et al., 1996; Shankar, et al., 2007) and hypercholesterolemia 
(Soedamah-Muthu, 2008). Hyperglycemia is associated with poor survival, also in patients 
with diabetes and ESRD (Ishimura, et al., 2009; Morioka, et al., 2001; Smavatkul, et al., 2007; 
Williams, et al., 2010), but evidence of the association with hypercholesterolemia is lacking 
(Foley, et al., 1997; Morioka, et al., 2001; Smavatkul, et al., 2007). These results are in line 
with our findings. Patients with diabetes on RRT are special also compared to other patients 
on RRT. Among ESRD patients, worse survival is in general shown to associate with 
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hyperphosphatemia (Lacson, et al., 2009; Trivedi, et al., 2005) and anemia (Avram, et al., 
2003; Lacson, et al., 2009; Locatelli, et al., 2004), but similar associations have not been 
found in the studies on ESRD patients with diabetes (Avram, et al., 2003; Foley, et al., 1997; 
Morioka, et al., 2001; Smavatkul, et al., 2007). In accordance with these results, low albumin 
(Coronel, et al., 2009; Foley, et al., 1997) and low predialysis phase creatinine (Morioka, et al., 
2001) have been shown to correlate with worse survival in patients with diabetes on RRT, 
although also nonsignificant correlation between albumin and mortality (Hocher, et al., 2007) 
and better survival associating with higher glomerular filtration  rate (Coronel, et al., 2009) 
have also been reported. High C-reactive protein as a marker of an ongoing inflammatory 
process is shown to associate with increased mortality among ESRD patients (Hocher, et al., 
2003; Panichi, et al., 2008), which is also in line with our findings. 
  
The prevalence of medication has not been studied previously during predialysis phase of 
kidney disease. However, studies among patients on RRT have reported 14–32% utilization of 
ACEIs, 31–70% of CCBs, 9–27% of beta-blockers, 10% of statins, and 13% of ARBs (Foley, 
et al., 2002; Griffith, et al., 2003; Ishani, et al., 2004; Lopes, et al., 2009). A markedly higher 
prevalence of medication was found here during predialysis phase. Reasons for this difference 
may include higher prevalence of comorbidities among ESRD patients with type 1 diabetes, 
earlier time period of these referred studies, and the common practice of discontinuing 
antihypertensive medication after RRT start. 
Only few randomized trials have studied the effect of medication use on survival in patients 
with predialysis phase or end-stage renal disease. These studies have not been able to show 
significant effect on mortality with use of statins (Baigent, et al., 2011; Fellstrom, et al., 2009; 
Wanner, et al., 2005). Randomised studies have shown that ACEIs and ARBs are beneficial in 
diabetic nephropathy by reducing albuminuria and slowing down progression of renal disease, 
but they did not find any effect on survival, although follow-up times were short (Brenner, et 
al., 2001; Lewis, et al., 2001). Mortality has not decreased in randomized trials aiming for 
higher hemoglobin levels with use of erythropoietin in patients with chronic kidney disease 
(Besarab, et al., 1998; Pfeffer, et al., 2009). When patients with ESRD and chronic heart 
failure were treated in addition to standard therapy with carvedilol or telmisartan, two 
randomized trials showed significant mortality risk reduction (Cice, et al., 2003; Cice, et al., 
2010). Recent meta-analysis reported that use of non-calcium-based phosphate binders was 
associated with lower mortality than use of calcium-based phosphate binders (Jamal, et al., 
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2013). Taken together, evidence that medicine utilization would improve survival among 
patients with predialysis phase or end-stage renal disease is scarce.  
 
A few large observational studies among ESRD patients have assessed associations between 
medicine utilization and survival. Better survival has been reported to associate with use of 
CCBs and not with beta-blockers (Griffith, et al., 2003; Ishani, et al., 2004; Kestenbaum, et al., 
2002). However, a large study from the United States reported opposite results (Foley, et al., 
2002). Use of statins or ARBs have also been reported to associate with better survival 
(Andreucci, et al., 2004; Ishani, et al., 2004; Lopes, et al., 2009). In hemodialysis patients low 
vitamin D (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D) concentration is reported to 
associate with higher mortality (Wolf, et al., 2007) and activated vitamin D injections 
(calcitriol or paricalcitol) to associate with improved survival (Teng, et al., 2005). The 
findings reported here on vitamin D utilization and mortality after RRT start are in line with 
these results. Thus, the evidence of a beneficial effect of medication on mortality is limited 
and partly conflicting. One reason for these contradictory results may be the difference in the 
patient cohorts. The cause of renal disesase and the number of comorbidities have a 
significant effect on mortality, and therefore the evaluation of correlation between medication 
and mortality is more reliable when assessed in more specifically defined patient groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
COCLUSIOS AD FUTURE PROSPECTS 
 
In summary, this work has demonstrated that the survival of patients with type 1 diabetes on 
RRT in Finland has improved during the last three decades. This improvement appears to be 
the result of development in RRT and diabetes management in addition to advancement of 
healthcare in general. These patients have more comorbidities than other patients on RRT, and 
comorbidities are significant predictors of death. Biochemical variables can be used to 
evaluate the risk of death when initiating RRT, and especially hypoalbuminemia and low 
creatinine concentration at start of RRT predict mortality. Patients with type 1 diabetes use 
abundant medication during the predialysis phase of renal disease, and the use of medication 
appeared to keep patients on an equal survival level to patients not on the same medication. 
Because these studies were observational and thus not ideal for assessing causal association 
between observed factors and survival, randomized trials are needed to confirm these findings. 
The results of these studies may be helpful when designing such trials.  
According to these results, effort should be put into diagnosis, early treatment, and 
particularly prevention of comorbidities in patients with type 1 diabetes and nephropathy. 
Treatment of malnutrition, proteinuria, and hyperglycemia, and efficient dialysis therapy 
appear important in attempt to improve survival of these patients on RRT in the future.  
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